U.S. patent number 10,864,252 [Application Number 16/173,701] was granted by the patent office on 2020-12-15 for anti-ssx-2 t cell receptors and related materials and methods of use.
This patent grant is currently assigned to The United States of Americans represented by the Secretary, Department of Health and Human Services. The grantee listed for this patent is The United States of America, as represented by the Secretary, Department of Health and Human Services, The United States of America, as represented by the Secretary, Department of Health and Human Services. Invention is credited to Nachimuthu Chinnasamy, Richard A. Morgan, Steven A. Rosenberg.
View All Diagrams
United States Patent |
10,864,252 |
Morgan , et al. |
December 15, 2020 |
Anti-SSX-2 T cell receptors and related materials and methods of
use
Abstract
The invention provides an isolated or purified T cell receptor
(TCR) having antigenic specificity for synovial sarcoma X
Breakpoint (SSX)-2. The invention further provides related
polypeptides and proteins, as well as related nucleic acids,
recombinant expression vectors, host cells, and populations of
cells. Further provided by the invention are antibodies, or an
antigen binding portion thereof, and pharmaceutical compositions
relating to the TCRs of the invention. Methods of detecting the
presence of cancer in a host and methods of treating or preventing
cancer in a host are further provided by the invention.
Inventors: |
Morgan; Richard A. (Columbia,
MD), Chinnasamy; Nachimuthu (North Potomac, MD),
Rosenberg; Steven A. (Potomac, MD) |
Applicant: |
Name |
City |
State |
Country |
Type |
The United States of America, as represented by the Secretary,
Department of Health and Human Services |
Bethesda |
MD |
US |
|
|
Assignee: |
The United States of Americans
represented by the Secretary, Department of Health and Human
Services (Bethesda, MD)
|
Family
ID: |
1000005242326 |
Appl.
No.: |
16/173,701 |
Filed: |
October 29, 2018 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20190054143 A1 |
Feb 21, 2019 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
15132863 |
Apr 19, 2016 |
10143724 |
|
|
|
13820802 |
May 24, 2016 |
9345748 |
|
|
|
PCT/US2011/051537 |
Sep 14, 2011 |
|
|
|
|
61384931 |
Sep 21, 2010 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
C07K
16/2809 (20130101); C07K 16/30 (20130101); C07K
14/7051 (20130101); A61K 38/1774 (20130101); A61K
38/08 (20130101); G01N 33/57492 (20130101); A61K
38/10 (20130101); A61K 39/39558 (20130101); A61K
31/706 (20130101); A61K 38/177 (20130101); C07K
2319/00 (20130101) |
Current International
Class: |
C07K
14/725 (20060101); G01N 33/574 (20060101); A61K
38/10 (20060101); C07K 16/28 (20060101); A61K
39/395 (20060101); C07K 16/30 (20060101); A61K
31/706 (20060101); A61K 38/17 (20060101); A61K
38/08 (20190101) |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
101001868 |
|
Jul 2007 |
|
CN |
|
0 239 400 |
|
Aug 1994 |
|
EP |
|
2 188 638 |
|
Oct 1987 |
|
GB |
|
2004-525354 |
|
Aug 2004 |
|
JP |
|
WO 2004/097052 |
|
Nov 2004 |
|
WO |
|
WO 2005/010190 |
|
Feb 2005 |
|
WO |
|
WO 2007/131092 |
|
Nov 2007 |
|
WO |
|
WO 2008/039694 |
|
Apr 2008 |
|
WO |
|
WO 2010/088160 |
|
Aug 2010 |
|
WO |
|
Other References
Ayyoub et al., "An immunodominant SSX-2-derived epitope recognized
by CD4+ T cells in association with HLA-DR," J. Clin. Invest.,
113(8): 1225-1233 (2004). cited by applicant .
Ayyoub et al., "Distinct but overlapping T helper epitopes in the
37-58 region of SSX-2," Clinical Immunology, 114: 70-78 (2005).
cited by applicant .
Ayyoub et al., "Proteasome-Assisted Identification of a
SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating
Metastatic Melanoma," J. Immunology, 168(4): 1717-1722 (2002).
cited by applicant .
Ayyoub et al., "Tumor-reactive, SSX-2-specific CD8+ T Cells Are
Selectively Expanded during Immune Responses to Antigen-expressing
Tumors in Melanoma Patients," Cancer Res., 63(17): 5601-5606
(2003). cited by applicant .
Chinese Patent Office, First Office Action in Chinese Patent
Application No. 2011800454920, dated Jun. 16, 2014. cited by
applicant .
Bricard et al., "Naturally Acquired MAGE-A10- and SSX-2-Specific
CD8+ T Cell Responses in Patients with Hepatocellular Carcinoma,"
J. Immunol., 174: 1709-1716 (2005). cited by applicant .
Caballero et al., "Cancer testis (CT) antigens: Potential targets
for immunotherapy," Cancer Sci., 100(11): 2014-2021 (2009). cited
by applicant .
Chinnasamy et al., "Development of HLA-A2 restricted TCR against
cancer testis antigen SSX-2 for adoptive immunotherapy of cancer,"
Abstract submitted to the International Society for Biological
Therapy of Cancer (ISBTC) annual meeting, Oct. 2-4, 2010. cited by
applicant .
Chinnasamy et al., "Development of T Cell Receptor Targeting the
HLA-A*0201 Restricted Epitope SSX2: 41-49 for Adoptive
Immunotherapy of Cancer," Poster Session: Cancer--Immunotherapy I
(4:40 pm-6:40 pm): May 19, 2011. cited by applicant .
Choi et al., "Synthesis and assembly of a cholera toxin B
subunit-rotavirus VP7 fusion protein in transgenic potato," Mol.
Biotechnol., 31(3): 193-202 (2005). cited by applicant .
"Evaluating subject Matter Eligibility Under 35 U.S.C. .sctn. 101,"
Mar. 19, 2014 update, pp. 1-93. cited by applicant .
GenBank Accession No. AB016436.1 (printed Sep. 23, 2008). cited by
applicant .
GenBank Accession No. ACF49241.1 (printed Jul. 26, 2008). cited by
applicant .
GenBank Accession No. ACF75415.1 (printed Aug. 2, 2008). cited by
applicant .
GenBank Accession No. A31326 (printed Jul. 23, 1999). cited by
applicant .
GenBank Accession No. CAB96920.1 (printed Jul. 8, 2000). cited by
applicant .
GenBank Accession No. NP_003138.3 XP_942599 (printed Mar. 14,
2009). cited by applicant .
Gure et al., "The SSX Gene Family: Characterization of 9 Complete
Genes," Int J. Cancer, 101: 448-453 (2002). cited by applicant
.
Haskard et al., "The production of human monoclonal autoantibodies
from patients with rheumatoid arthritis by the EBV-hybridoma
technique," J. Immunol. Methods, 74(2): 361-367 (1984). cited by
applicant .
He et al., "Identification of a common HLA-A*0201-restricted
epitope among SSX family members by mimicking altered peptide
ligands strategy," Mol. Immunol., 45(9): 2455-2464 (2008). cited by
applicant .
Hudecz, "Synthesis of peptide bioconjugates," Methods Mol. Biol.,
298: 209-223 (2005). cited by applicant .
Huse et al., "Generation of a large combinatorial library of the
immunoglobulin repertoire in phage lambda," Science, 246(4935):
1275-1281 (1989). cited by applicant .
International Bureau, International Preliminary Report on
Patentability in International Application No. PCT/US2011/051537,
dated Mar. 26, 2013. cited by applicant .
International Bureau, International Search Report in International
Application No. PCT/US2011/051537, dated Mar. 29, 2012. cited by
applicant .
International Bureau, Written Opinion of the International
Searching Authority in International Application No.
PCT/US2011/051537, dated Mar. 21, 2013. cited by applicant .
Jakobsen, "Soluble, High Affinity T Cell Receptors as Cancer
Therapeutics," iSBTc 24.sup.th Annual Meeting, p. 1-18 (Oct. 29-31,
2009). cited by applicant .
Kirin et al., "Amino acid and peptide bioconjugates of copper(II)
and zinc(II) complexes with a modified N,N-bis(2-picolyl)amine
ligand," Inorg Chem., 44(15): 5405-5415 (2005). cited by applicant
.
Kohler et al., "Derivation of specific antibody-producing tissue
culture and tumor lines by cell fusion," Eur. J. Immunol., 6(7):
511-519 (1976). cited by applicant .
Li et al., "Directed evolution of human T-cell receptors with
picomolar affinities by phage display," Nat. Biotechnol., 23(3):
349-54 (2005). cited by applicant .
Pedersen et al., "Comparison of surface accessible residues in
human and murine immunoglobulin Fv domains. Implication for
humanization of murine antibodies," J. Mol. Biol., 235(3): 959-973
(1994). cited by applicant .
Reiter et al., "Engineering interchain disulfide bonds into
conserved framework regions of Fv fragments: improved biochemical
characteristics of recombinant immunotoxins containing
disulfide-stabilized Fv," Protein Eng., 7(5): 697-704 (1994). cited
by applicant .
Richman et al., "Display, engineering, and applications of
antigen-specific T cell receptors," BioEng., 24(4): 361-373 (2007).
cited by applicant .
Roder et al., "The EBV-hybridoma technique," Methods Enzymol., 121:
140-167 (1986). cited by applicant .
Taylor et al., "SSX Cancer Testis Antigens are Expressed in Most
Multiple Myeloma Patients: Co-Expression of SSX1, 2, 4, and 5
Correlates With Adverse Prognosis and High Frequencies of
SSX-Positive PCs," J. Immunother, 28: 564-575 (2005). cited by
applicant .
The Memorandum from Deputy Commissioner for Patent Examination
Policy Andrew H. Hirshfeld, dated Mar. 4, 2014, 19 pages. cited by
applicant .
Tureci et al., "Expression of SSX genes in human tumors," Int. J.
Cancer, 77: 19-23 (1998). cited by applicant .
Wadwa et al., "Receptor mediated glycotargeting," J. Drug Target.,
3(2): 111-127 (1995). cited by applicant .
Murphy et al., "T-cell receptors concentrate diversity in the third
hypervariable region," Janeway's Immunobiology, 7.sup.th Edition,
p. 157-158 (2008). cited by applicant .
U.S. Appl. No. 15/132,863, filed Apr. 19, 2016. cited by applicant
.
U.S. Appl. No. 13/820,802, filed Jun. 7, 2013. cited by
applicant.
|
Primary Examiner: Skelding; Zachary S
Attorney, Agent or Firm: Leydig, Voit & Mayer
Government Interests
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH AND
DEVELOPMENT
This invention was made with Government support under project
number BC010985 by the National Institutes of Health, National
Cancer Institute. The Government has certain rights in the
invention.
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATIONS
This patent application is a continuation of U.S. application Ser.
No. 15/132,863, filed Apr. 19, 2016, which is a divisional of U.S.
application Ser. No. 13/820,802, now U.S. Pat. No. 9,345,748, which
is the U.S. national phase of International Patent Application No.
PCT/US2011/051537, filed Sep. 14, 2011, which claims the benefit of
U.S. Provisional Patent Application No. 61/384,931, filed Sep. 21,
2010, each of which is incorporated by reference in its entirety
herein.
Claims
The invention claimed is:
1. A recombinant expression vector comprising a nucleic acid
comprising a nucleotide sequence encoding a T cell receptor (TCR)
having antigenic specificity for synovial sarcoma X Breakpoint
(SSX)-2 (SEQ ID NO: 1), wherein the TCR comprises SEQ ID NOs: 19
and 20.
2. The recombinant expression vector of claim 1, wherein the TCR
also recognizes any one or more of SSX-3 (SEQ ID NO: 3), SSX-4 (SEQ
ID NO: 4), SSX-5 (SEQ ID NO: 5), SSX-9 (SEQ ID NO: 6), and SSX-10
(SEQ ID NO: 7).
3. The recombinant expression vector of claim 1, wherein the TCR
has antigenic specificity for an SSX-2 peptide comprising KASEKIFYV
(SEQ ID NO: 2).
4. The recombinant expression vector of claim 1, wherein the TCR
recognizes any one or more of KVSEKIVYV (SEQ ID NO: 8), KSSEKIVYV
(SEQ ID NO: 9), KASEKIIYV (SEQ ID NO: 10), KSSEKIIYV (SEQ ID NO:
11), and KASEKILYV (SEQ ID NO: 12).
5. The recombinant expression vector of claim 1, wherein the TCR
further comprises SEQ ID NOs: 21 and 22.
6. The recombinant expression vector of claim 1, wherein the TCR
comprises: a) SEQ ID NO: 23 and 24 or b) SEQ ID NO: 25 and 26.
7. A recombinant expression vector comprising a nucleic acid
comprising a nucleotide sequence encoding a polypeptide comprising
the amino acid sequences of SEQ ID NOs: 13-18.
8. The recombinant expression vector of claim 7, wherein the
polypeptide comprises the amino acid sequences of SEQ ID NOs: 19
and 20.
9. The recombinant expression vector of claim 8, wherein the
polypeptide comprises: a) SEQ ID NO: 23 and 24; or b) SEQ ID NO: 25
and 26.
10. A recombinant expression vector comprising a nucleic acid
comprising a nucleotide sequence encoding a protein comprising a
first polypeptide chain comprising SEQ ID NO: 19 and a second
polypeptide chain comprising SEQ ID NO: 20.
11. The recombinant expression vector of claim 10, wherein the
protein comprises: a) a first polypeptide chain comprising SEQ ID
NO: 23 and a second polypeptide chain comprising SEQ ID NO: 24; or
b) a first polypeptide chain comprising SEQ ID NO: 25 and a second
polypeptide chain comprising SEQ ID NO: 26.
12. The recombinant expression vector of claim 10, wherein the
protein is a fusion protein.
13. The recombinant expression vector of claim 10, wherein the
protein is a recombinant antibody.
14. The recombinant expression vector of claim 1, wherein the
vector is a retroviral vector.
15. An isolated host cell comprising the recombinant expression
vector of claim 1.
16. The isolated host cell of claim 15, wherein the cell is a
peripheral blood lymphocyte (PBL).
17. The isolated host cell of claim 16, wherein the PBL is a CD8+ T
cell or a CD4+ T cell.
18. A population of cells comprising at least one host cell of
claim 15.
19. A pharmaceutical composition comprising the recombinant
expression vector of claim 1 and a pharmaceutically acceptable
carrier.
20. A method of detecting the presence of cancer which expresses
the amino acid sequence of KASEKIFYV (SEQ ID NO: 2) presented by an
HLA-A2 molecule in a host, comprising: (a) contacting a sample
comprising cells of the cancer with the population of cells of
claim 18, thereby forming a complex, and (b) detecting the complex,
wherein detection of the complex is indicative of the presence of
the cancer which expresses the amino acid sequence of KASEKIFYV
(SEQ ID NO: 2) presented by the HLA-A2 molecule in the host.
21. A method of treating cancer which expresses the amino acid
sequence of KASEKIFYV (SEQ ID NO: 2) presented by an HLA-A2
molecule in a host, comprising administering to the host the
population of cells of claim 18, in an amount effective to treat
the cancer which expresses the amino acid sequence of KASEKIFYV
(SEQ ID NO: 2) presented by the HLA-A2 molecule in the host,
wherein the cancer is ovarian cancer, glioma, melanoma, or
hepatocellular carcinoma.
22. The method of claim 20, wherein the cancer is selected from the
group consisting of head-neck cancer, ovarian cancer, lung cancer,
glioma, melanoma, renal cancer, lymphoma, colon cancer, pancreatic
cancer, breast cancer, prostate cancer, synovial sarcoma,
osteogenic sarcoma, leiomyosarcoma uteri, and hepatocellular
carcinoma.
23. The method of claim 20, wherein the host cells comprise the
recombinant expression vector and are autologous to the host.
24. The method of claim 21, further comprising administering
5-aza-2'-deoxycytidine (DAC) to the host.
25. A pharmaceutical composition comprising the population of cells
of claim 18 and a pharmaceutically acceptable carrier.
Description
INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY
Incorporated by reference in its entirety herein is a
computer-readable nucleotide/amino acid sequence listing submitted
concurrently herewith and identified as follows: One 41,613 Byte
ASCII (Text) file named "740795_ST25.txt," dated Oct. 24, 2018.
BACKGROUND OF THE INVENTION
Adoptive cell therapy (ACT) involves the transfer of reactive T
cells into patients, including the transfer of tumor-reactive T
cells into cancer patients. Adoptive cell therapy has been
successful in causing the regression of tumors in some cancers,
e.g., melanoma. One obstacle to the widespread application of
adoptive cell therapy is the difficulty in generating human T cells
with anti-tumor potential. Another obstacle to the successful
application of adoptive cell therapy is that the transferred T
cells can also be toxic to normal, i.e., non-cancerous tissues.
Accordingly, there exists a need for improved immunological
compositions and methods for treating cancer.
BRIEF SUMMARY OF THE INVENTION
The invention provides an isolated or purified T cell receptor
(TCR) having antigenic specificity for synovial sarcoma X
Breakpoint (SSX)-2 (SEQ ID NO: 1). The TCR can comprise specified
amino acid sequences as described herein. For instance, the
inventive TCR can comprise the amino acid sequence of any one or
more of SEQ ID NOs: 13-18, SEQ ID NOs: 19 and 20, SEQ ID NOs: 23
and 24, or SEQ ID NOs: 25 and 26.
The invention further provides related polypeptides and proteins,
as well as related nucleic acids, recombinant expression vectors,
host cells, and populations of cells. Further provided by the
invention are antibodies, or an antigen binding portion thereof,
and pharmaceutical compositions relating to the TCRs of the
invention.
Methods of detecting the presence of cancer in a host and methods
of treating or preventing cancer in a host are further provided by
the invention. The inventive method of detecting the presence of
cancer in a host comprises (i) contacting a sample comprising cells
of the cancer with any of the inventive TCRs, polypeptides,
proteins, nucleic acids, recombinant expression vectors, host
cells, populations of host cells, or antibodies, or antigen binding
portions thereof, described herein, thereby forming a complex, and
(ii) detecting the complex, wherein detection of the complex is
indicative of the presence of cancer in the host.
The inventive method of treating or preventing cancer in a host
comprises administering to the host any of the TCRs, polypeptides,
or proteins described herein, any nucleic acid or recombinant
expression vector comprising a nucleotide sequence encoding any of
the TCRs, polypeptides, proteins described herein, or any host cell
or population of host cells comprising a recombinant vector which
encodes any of the TCRs, polypeptides, or proteins described
herein, in an amount effective to treat or prevent cancer in the
host.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1A is a bar graph showing interferon-.gamma. (IFN-.gamma.)
levels measured after SSX-2 TCR-transduced peripheral blood
leukocytes (PBLs) were co-cultured with T2 cells from a human
donor, wherein the T2 cells were pulsed with varying concentrations
of the SSX-2: 41-49 (KASEKIFYV) (SEQ ID NO: 2) peptide.
FIG. 1B is a bar graph showing IFN-.gamma. levels measured, as in
FIG. 1A, except the T2 cells were from a different human donor.
FIG. 2 is a bar graph showing IFN-.gamma. levels measured when
SSX-2 TCR-transduced PBLs were co-cultured with 293-A2 and COST-A2
cells expressing the SSX-2 gene and T2 cells pulsed with the SSX-2:
41-49 peptide.
FIG. 3 is a bar graph that shows the resulting IFN-.gamma. levels
measured when SSX-2 TCR-transduced PBLs (shaded bars) or
untransduced (UT) PBLs (unshaded bars) were co-cultured with
various tumor cell lines.
FIG. 4A is a bar graph that shows IFN-.gamma. levels after PBLs
from a human donor, that were transduced with a SSX-2 TCR (shaded
bars) or not transduced (UT) (unshaded bars), were co-cultured with
various tumor cells.
FIG. 4B is a bar graph that shows IFN-.gamma. levels, as in FIG.
4A, except the PBLs were from a different human donor.
FIG. 5 is a line graph that shows the results of co-culture assays
performed with SSX-2 TCR transduced-PBLs and peptide-pulsed T2
cells. The peptides used for pulsing were: SSX-1 (KYSEKISYV, SEQ ID
NO: 32) (-.diamond-solid.-); SSX-2 (KASEKIFYV, SEQ ID NO: 2)
(.box-solid.); SSX-3 (KVSEKIVYV, SEQ ID NO: 8) (.box-solid.); SSX-4
(KSSEKIVYV, SEQ ID NO: 9) (X); SSX-5 (KASEKIIYV, SEQ ID NO: 10) ();
SSX-6 (KFSEKISCV, SEQ ID NO: 33) (.cndot.); SSX-7 (KSLEKISYV, SEQ
ID NO: 34) (|); SSX-8 KYSEKISYV, SEQ ID NO: 32) (-); SSX-9
(KSSEKIIYV, SEQ ID NO: 11) (--); and SSX-10 (KASEKILYV, SEQ ID NO:
12) (--.diamond-solid.--).
FIGS. 6A and 6B are bar graphs showing proliferation (in terms of
[.sup.3H]-thymidine incorporation counts per minute (CPM)) of PBLs
from Donor 1 (A) or Donor 2 (B) that were untransduced (UT) or
transduced with SSX-2 TCR ("SSX-WT"), codon-optimized SSX-2 TCR
("SSX-CO op"), or a codon-optimized human-mouse chimera SSX-2 TCR
("SSX-MCR").
FIGS. 7A-D are graphs showing percent lysis of 938 mel
(HLA-A2-/SSX-2+) (A), COS-A2 (B), 938-A2 mel (C), COS-A2-SSX-2 (D)
when co-cultured with PBL that were untransduced (.diamond-solid.)
or transduced with SSX-2 TCR (.box-solid.), codon-optimized SSX-2
TCR (.tangle-solidup.), or a codon-optimized human-mouse chimera
SSX-2 TCR (X) at the indicated effector to target (E:T) ratios.
FIGS. 8A-D are line graphs showing percent lysis of 624 mel (A),
1300 mel (B), SK mel 37 (C), or 888 mel (D) when co-cultured with
PBL that were untransduced (.diamond-solid.) or transduced with
SSX-2 TCR (.box-solid.), codon-optimized SSX-2 TCR
(.tangle-solidup.), or a codon-optimized human-mouse chimera SSX-2
TCR (X) at the indicated effector to target (E:T) ratios.
FIGS. 9A-9E are bar graphs showing proliferation (in terms of
[.sup.3H]-thymidine incorporation counts per minute (CPM)) of PBLs
that were untransduced or transduced with SSX-2 TCR ("SSX-TCR-WT"),
codon-optimized SSX-2 TCR ("SSX-TCR-codon optimized-PBL"), or a
codon-optimized human-mouse chimera SSX-2 TCR ("SSX-2-TCR mouse
constant region-PBL").
FIG. 10 is a bar graph showing IFN-.gamma. levels measured after
PBLs transduced with SSX-2 TCR ("SSX2-WT") (grey bars),
codon-optimized SSX-2 TCR ("SSX2-Co Op") (unshaded bars), or a
codon-optimized human-mouse chimera SSX-2 TCR ("SSX2-MCR") (black
bars) were co-cultured with T2 cells from a human donor, wherein
the T2 cells were pulsed with varying concentrations of the SSX-2:
41-49 peptide.
FIG. 11 is a bar graph that shows IFN-.gamma. levels after PBLs
from a human donor, that were transduced with a SSX-2 TCR (unshaded
bars) or not transduced (UT) (shaded bars), were co-cultured with
various primary melanoma cells.
FIG. 12 is a bar graph that shows IFN-.gamma. levels after PBLs
from a human donor that were transduced with a SSX-2 TCR were
co-cultured with mel1300 cells in the absence (grey bars) or in the
presence (0.1 .mu.M (unshaded bars) or 1.0 .mu.M (black bars)) of
the demethylating agent, 5-aza-2'-deoxycytidine (DAC). NM is normal
media with no drug control.
DETAILED DESCRIPTION OF THE INVENTION
The invention provides an isolated or purified T cell receptor
(TCR) having antigenic specificity for synovial sarcoma X
breakpoint (SSX)-2 (also known as HOM-MEL-40). SSX-2 is a member of
the SSX family of ten highly homologous nuclear proteins also
including SSX-1, SSX-3, SSX-4, SSX-5, SSX-6, SSX-7, SSX-8, SSX-9,
and SSX-10. The SSX proteins are cancer testis antigens (CTA),
which are expressed only in tumor cells and non-MHC expressing germ
cells of the testis. SSX-2 is expressed in a variety of human
cancers including, but not limited to, melanomas, head cancers,
neck cancers, lymphomas, multiple myeloma, pancreatic cancer,
prostate cancer, sarcomas, hepatocellular and colon carcinomas. The
SSX-2 protein may comprise, consist, or consist essentially of, SEQ
ID NO: 1.
The phrase "antigenic specificity" as used herein means that the
TCR can specifically bind to and immunologically recognize SSX-2
with high avidity. For example, a TCR may be considered to have
"antigenic specificity" for SSX-2 if T cells expressing the TCR
secrete at least about 200 pg/ml or more (e.g., 200 pg/ml or more,
300 pg/ml or more, 400 pg/ml or more, 500 pg/ml or more, 600 pg/ml
or more, 700 pg/ml or more) of IFN-.gamma. upon co-culture with a
low concentration of HLA-A2 restricted SSX-2 (e.g., about 0.01
ng/ml to about 1 ng/ml, 0.01 ng/ml, 0.1 ng/ml, or 1 ng/ml). The
inventive TCRs may also secrete IFN-.gamma. upon co-culture with
higher concentrations of SSX-2.
An embodiment of the present invention includes an isolated or
purified T cell receptor (TCR) having antigenic reactivity toward
synovial sarcoma X Breakpoint (SSX)-2 or SSX-2 and any one or more
of SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10.
The TCR may have antigenic specificity for any SSX-2 protein,
polypeptide or peptide. In an embodiment of the invention, the TCR
has antigenic specificity for an SSX-2 protein comprising,
consisting of, or consisting essentially of, SEQ ID NO: 1. In a
preferred embodiment of the invention, the TCR has antigenic
specificity for an SSX-2 peptide comprising, consisting of, or
consisting essentially of, KASEKIFYV (SEQ ID NO: 2).
While the TCRs of the invention have antigenic specificity for
SSX-2, the TCRs of the invention can also recognize any one or more
of SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10. That is, the TCRs of the
invention can bind to and immunologically recognize any one or more
of SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10, but with a lower avidity
than that which is observed for binding to SSX-2, such that the
binding of the TCR to one of these proteins elicits an immune
response at a higher concentration of any one of these proteins
than that which is necessary to elicit an immune response with
SSX-2. For example, the TCR of the invention may be considered to
recognize any one or more of SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10
with low avidity if T cells expressing the TCR do not secrete at
least about 200 pg/ml (e.g., secretes less than 200 pg/ml, less
than 100 pg/ml) of IFN-.gamma. upon co-culture with a low
concentration of any one or more of SSX-3, SSX-4, SSX-5, SSX-9, and
SSX-10 (e.g., about 0.01 ng/ml to about 1 ng/ml, 0.01 ng/ml, 0.1
ng/ml, or 1 ng/ml) but do secrete at least about 200 pg/ml or more
(e.g., 200 pg/ml or more, 300 pg/ml or more, 400 pg/ml or more, 500
pg/mi or more, 600 pg/ml or more, 700 pg/ml or more) upon
co-culture with a higher concentration of any one or more of SSX-3,
SSX-4, SSX-5, SSX-9, and SSX-10 (e.g., about 10 ng/ml to about 100
ng/ml, 10 ng/ml, 50 ng/ml, or 100 ng/ml).
The TCR may recognize an SSX-3, SSX-4, SSX-5, SSX-9, and/or SSX-10
protein, polypeptide or peptide. In an embodiment of the invention,
the TCR recognizes a protein comprising, consisting of, or
consisting essentially of, SEQ ID NO: 3 (SSX-3), SEQ ID NO: 4
(SSX-4), SEQ ID NO: 5 (SSX-5), SEQ ID NO: 6 (SSX-9), and/or SEQ ID
NO: 7 (SSX-10). In a preferred embodiment of the invention, the TCR
recognizes a peptide comprising, consisting of, or consisting
essentially of, SSX-3 peptide KVSEKIVYV (SEQ ID NO: 8), SSX-4
peptide KSSEKIVYV (SEQ ID NO: 9), SSX-5 peptide KASEKIIYV (SEQ ID
NO: 10), SSX-9 peptide KSSEKIIYV (SEQ ID NO: 11), and/or SSX-10
peptide KASEKILYV (SEQ ID NO: 12).
The inventive TCRs are able to recognize SSX-2, SSX-3, SSX-4,
SSX-5, SSX-9, and/or SSX-10 (hereinafter, "SSX cancer antigens") in
an HLA-A2-dependent manner. By "HLA-A2-dependent manner" as used
herein means that the TCR elicits an immune response upon binding
to an SSX cancer antigen within the context of an HLA-A2
molecule.
Furthermore, without being bound to any particular theory, the
inventive TCRs are able to recognize an SSX cancer antigen in a
CD8- and/or CD4-independent manner. By "CD8- and/or CD4-independent
manner," is meant that the inventive TCRs, upon binding to an SSX
cancer antigen, can elicit an immune response in the absence of a
CD8 or CD4 molecule, or both a CD8 and CD4 molecule, expressed on
the cell expressing the inventive TCR or in the absence of a
functional CD8 or CD4 molecule, or both. Unlike traditional TCRs,
the inventive TCRs do not have a preference for CD8 or CD4 and can
function in the context of either a CD8 or CD4 molecule.
The TCRs of the invention provide many advantages, including when
used for adoptive cell transfer. For example, without being bound
by a particular theory, it is believed that because SSX-2, SSX-3,
SSX-4, SSX-5, SSX-9, and/or SSX-10 are expressed by cells of
multiple cancer types, the inventive TCRs advantageously provide
the ability to destroy cells of multiple types of cancer and,
accordingly, treat or prevent multiple types of cancer.
Additionally, without being bound to a particular theory, it is
believed that because the SSX proteins are cancer testis antigens
that are expressed only in tumor cells and non-MHC expressing germ
cells of the testis, the inventive TCRs advantageously target the
destruction of cancer cells while minimizing or eliminating the
destruction of normal, non-cancerous cells, thereby reducing, for
example, minimizing or eliminating, toxicity. In addition, while
the inventive TCRs have antigenic specificity for SSX-2, the
inventive TCRs advantageously also recognize any one or more of
SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10. Without being bound to a
particular theory, it is believed that the ability to recognize
multiple cancer antigens advantageously increases the number of
cancer cells that can be destroyed by the inventive TCRs.
Additionally, should an SSX antigen become mutated, the inventive
TCRs can still be viable in that they recognize more than just one
antigen.
The invention provides a TCR comprising two polypeptides (i.e.,
polypeptide chains), such as an .alpha. chain of a TCR, a .beta.
chain of a TCR, a .gamma. chain of a TCR, a .delta. chain of a TCR,
or a combination thereof. Such polypeptides chains of TCRs are
known in the art. The polypeptides of the inventive TCR can
comprise any amino acid sequence, provided that the TCR has
antigenic specificity for SSX-2 and/or recognizes any one or more
of SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10.
In an embodiment of the invention, the TCR comprises two
polypeptide chains, each of which comprises a variable region
comprising a complementarity determining region (CDR) 1, a CDR2,
and a CDR3 of a TCR. Preferably, the first polypeptide chain
comprises a CDR1 comprising the amino acid sequence of SEQ ID NO:
13 (CDR1 of a chain), a CDR2 comprising the amino acid sequence of
SEQ ID NO: 14 (CDR2 of a chain), and a CDR3 comprising the amino
acid sequence of SEQ ID NO: 15 (CDR3 of a chain), and the second
polypeptide chain comprises a CDR1 comprising the amino acid
sequence of SEQ ID NO: 16 (CDR1 of .beta. chain), a CDR2 comprising
the amino acid sequence of SEQ ID NO: 17 (CDR2 of .beta. chain),
and a CDR3 comprising the amino acid sequence of SEQ ID NO: 18
(CDR3 of .beta. chain). In this regard, the inventive TCR can
comprise the amino acid sequences selected from the group
consisting of any one or more of SEQ ID NOs: 13-15, 16-18, and
13-18. Preferably the TCR comprises the amino acid sequences of SEQ
ID NOs: 13-18.
Alternatively or additionally, the TCR can comprise an amino acid
sequence of a variable region of a TCR comprising the CDRs set
forth above. In this regard, the TCR can comprise the amino acid
sequence of SEQ ID NO: 19 (the variable region of an .alpha. chain)
or 20 (the variable region of a .beta. chain), both SEQ ID NOs: 19
and 20, SEQ ID NO: 35 (a portion of the variable region of an
.alpha. chain) or 36 (a portion of the variable region of a chain),
or both SEQ ID NOs: 35 and 36. Preferably, the inventive TCR
comprises the amino acid sequences of SEQ ID NOs: 19 and 20.
Alternatively or additionally, the TCR can comprise an .alpha.
chain of a TCR and a .beta. chain of a TCR. Each of the .alpha.
chain and .beta. chain of the inventive TCR can independently
comprise any amino acid sequence. Preferably, the .alpha. chain
comprises the variable region of an .alpha. chain as set forth
above. In this regard, the inventive TCR can comprise the amino
acid sequence of SEQ ID NO: 23. An inventive TCR of this type can
be paired with any .beta. chain of a TCR. Preferably, the .beta.
chain of the inventive TCR comprises the variable region of a
.beta. chain as set forth above. In this regard, the inventive TCR
can comprise the amino acid sequence of SEQ ID NO: 24. The
inventive TCR, therefore, can comprise the amino acid sequence of
SEQ ID NO: 23 or 24, or both SEQ ID NOs: 23 and 24. Preferably, the
inventive TCR comprises the amino acid sequences of SEQ ID NOs: 23
and 24.
In an embodiment of the invention, the TCR can comprise a
human/mouse chimeric TCR. In this regard, the TCR can comprise a
mouse constant region comprising SEQ ID NO: 21 (mouse constant
region of an .alpha. chain), SEQ ID NO: 22 (mouse constant region
of .beta. chain), or both SEQ ID NOs: 21 and 22. Preferably, the
TCR comprises both SEQ ID NOs: 21 and 22.
Alternatively or additionally, the inventive human/mouse chimeric
TCR can comprise any of the CDRs set forth above. In this regard,
the inventive human/mouse chimeric TCR can comprise the amino acid
sequences selected from the group consisting of SEQ ID NOs: 13-15,
16-18, and 13-18. Preferably the human/mouse chimeric TCR comprises
the amino acid sequences of SEQ ID NOs: 13-18.
Alternatively or additionally, the human/mouse chimeric TCR can
comprise any of the variable regions set forth above. In this
regard, the inventive human/mouse chimeric TCR can comprise the
amino acid sequence of SEQ ID NO: 19 (the variable region of an
.alpha. chain) or 20 (the variable region of a .beta. chain), both
SEQ ID NOs: 19 and 20, SEQ ID NO: 35 (a portion of the variable
region of an .alpha. chain) or 36 (a portion of the variable region
of a .beta. chain), or both SEQ ID NOs: 35 and 36. Preferably, the
inventive TCR comprises the amino acid sequences of SEQ ID NOs: 19
and 20.
Alternatively or additionally, the human/mouse chimeric TCR can
comprise an .alpha. chain of a TCR and a .beta. chain of a TCR.
Each of the .alpha. chain and .beta. chain of the inventive
human/mouse chimeric TCR can independently comprise any amino acid
sequence. Preferably, the .alpha. chain comprises the variable
region of an .alpha. chain as set forth above. In this regard, the
inventive human/mouse chimeric TCR can comprise the amino acid
sequence of SEQ ID NO: 25. An inventive human/mouse chimeric TCR of
this type can be paired with any .beta. chain of a TCR. Preferably,
the .beta. chain of the inventive human/mouse chimeric TCR
comprises the variable region of a .beta. chain as set forth above.
In this regard, the inventive human/mouse chimeric TCR can comprise
the amino acid sequence of SEQ ID NO: 26. The inventive human/mouse
chimeric TCR, therefore, can comprise the amino acid sequence of
SEQ ID NO: 25 or 26, or both SEQ ID NOs: 25 and 26. Preferably, the
inventive TCR comprises the amino acid sequences of SEQ ID NOs: 25
and 26.
Also provided by the invention is an isolated or purified
polypeptide comprising a functional portion of any of the TCRs
described herein. The Willi "polypeptide" as used herein includes
oligopeptides and refers to a single chain of amino acids connected
by one or more peptide bonds.
With respect to the inventive polypeptides, the functional portion
can be any portion comprising contiguous amino acids of the TCR of
which it is a part, provided that the functional portion
specifically binds to SSX-2 and/or recognizes any one or more of
SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10. The term "functional
portion" when used in reference to a TCR refers to any part or
fragment of the TCR of the invention, which part or fragment
retains the biological activity of the TCR of which it is a part
(the parent TCR). Functional portions encompass, for example, those
parts of a TCR that retain the ability to specifically bind to
SSX-2 and/or recognize any one or more of SSX-3, SSX-4, SSX-5,
SSX-9, and SSX-10 (e.g., in an HLA-A2-dependent manner), or detect,
treat, or prevent cancer, to a similar extent, the same extent, or
to a higher extent, as the parent TCR. In reference to the parent
TCR, the functional portion can comprise, for instance, about 10%,
25%, 30%, 50%, 68%, 80%, 90%, 95%, or more, of the parent TCR.
The functional portion can comprise additional amino acids at the
amino or carboxy terminus of the portion, or at both termini, which
additional amino acids are not found in the amino acid sequence of
the parent TCR. Desirably, the additional amino acids do not
interfere with the biological function of the functional portion,
e.g., specifically binding to SSX-2; recognizing any one or more of
SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10; having the ability to
detect cancer, treat or prevent cancer, etc. More desirably, the
additional amino acids enhance the biological activity, as compared
to the biological activity of the parent TCR.
The polypeptide can comprise a functional portion of either or both
of the .alpha. and .beta. chains of the TCRs of the invention, such
as a functional portion comprising one of more of CDR1, CDR2, and
CDR3 of the variable region(s) of the .alpha. chain and/or .beta.
chain of a TCR of the invention. In this regard, the polypeptide
can comprise a functional portion comprising the amino acid
sequence of SEQ ID NO: 13 (CDR1 of .alpha. chain), 14 (CDR2 of
.alpha. chain), 15 (CDR3 of .alpha. chain), 16 (CDR1 of .beta.
chain), 17 (CDR2 of .beta. chain), 18 (CDR3 of .beta. chain), or a
combination thereof. Preferably, the inventive polypeptide
comprises a functional portion comprising SEQ ID NOs: 13-15, 16-18,
or all of SEQ ID NOs: 13-18. More preferably, the polypeptide
comprises a functional portion comprising the amino acid sequences
of SEQ ID NOs: 13-18.
Alternatively or additionally, the inventive polypeptide can
comprise, for instance, the variable region of the inventive TCR
comprising a combination of the CDR regions set forth above. In
this regard, the polypeptide can comprise the amino acid sequence
of SEQ ID NO: 19 (the variable region of an .alpha. chain), 20 (the
variable region of a .beta. chain), both SEQ ID NOs: 19 and 20, SEQ
ID NO: 35 (a portion of the variable region of an .alpha. chain) or
36 (a portion of the variable region of a .beta. chain), or both
SEQ ID NOs: 35 and 36. Preferably, the polypeptide comprises the
amino acid sequence of SEQ ID NO: 19, SEQ ID NO: 20, or the amino
acid sequences of both SEQ ID NOs: 19 and 20.
Alternatively or additionally, the inventive polypeptide can
comprise the entire length of an .alpha. or .beta. chain of one of
the TCRs described herein. In this regard, the inventive
polypeptide can comprise an amino acid sequence of SEQ ID NOs: 23,
24, 25, or 26. Alternatively, the polypeptide of the invention can
comprise .alpha. and .beta. chains of the TCRs described herein.
For example, the inventive polypeptide can comprise the amino acid
sequences of both SEQ ID NOs: 23 and 24 or the sequences of both
SEQ ID NOs: 25 and 26.
The invention further provides an isolated or purified protein
comprising at least one of the polypeptides described herein. By
"protein" is meant a molecule comprising one or more polypeptide
chains.
The protein of the invention can comprise a first polypeptide chain
comprising the amino acid sequence of SEQ ID NO: 19 or 35 and a
second polypeptide chain comprising the amino acid sequence of SEQ
ID NO: 20 or 36. The protein of the invention can, for example,
comprise a first polypeptide chain comprising the amino acid
sequence of SEQ ID NO: 23 or 25 and a second polypeptide chain
comprising the amino acid sequence of SEQ ID NO: 24 or 26. In this
instance, the protein of the invention can be a TCR. Alternatively,
if, for example, the protein comprises a single polypeptide chain
comprising SEQ ID NO: 23 or 25 and SEQ ID NO: 24 or 26, or if the
first and/or second polypeptide chain(s) of the protein further
comprise(s) other amino acid sequences, e.g., an amino acid
sequence encoding an immunoglobulin or a portion thereof, then the
inventive protein can be a fusion protein. In this regard, the
invention also provides a fusion protein comprising at least one of
the inventive polypeptides described herein along with at least one
other polypeptide. The other polypeptide can exist as a separate
polypeptide of the fusion protein, or can exist as a polypeptide,
which is expressed in frame (in tandem) with one of the inventive
polypeptides described herein. The other polypeptide can encode any
peptidic or proteinaceous molecule, or a portion thereof,
including, but not limited to an immunoglobulin, CD3, CD4, CD8, an
MHC molecule, a CD1 molecule, e.g., CD1a, CD1b, CD1c, CD1d,
etc.
The fusion protein can comprise one or more copies of the inventive
polypeptide and/or one or more copies of the other polypeptide. For
instance, the fusion protein can comprise 1, 2, 3, 4, 5, or more,
copies of the inventive polypeptide and/or of the other
polypeptide. Suitable methods of making fusion proteins are known
in the art, and include, for example, recombinant methods. See, for
instance, Choi et al., Mol. Biotechnol. 31: 193-202 (2005).
In some embodiments of the invention, the TCRs, polypeptides, and
proteins of the invention may be expressed as a single protein
comprising a linker peptide linking the .alpha. chain and the
.beta. chain. In this regard, the TCRs, polypeptides, and proteins
of the invention may further comprise a linker peptide comprising
an amino acid sequence comprising SEQ ID NO: 37. In an embodiment
of the invention, the linker peptide may be encoded by a nucleotide
sequence comprising SEQ ID NO: 38. The linker peptide may
advantageously facilitate the expression of a recombinant TCR,
polypeptide, and/or protein in a host cell. Upon expression of the
construct including the linker peptide by a host cell, the linker
peptide may be cleaved, resulting in separated .alpha. and .beta.
chains.
The protein of the invention can be a recombinant antibody
comprising at least one of the inventive polypeptides described
herein. As used herein, "recombinant antibody" refers to a
recombinant (e.g., genetically engineered) protein comprising at
least one of the polypeptides of the invention and a polypeptide
chain of an antibody, or a portion thereof. The polypeptide of an
antibody, or portion thereof, can be a heavy chain, a light chain,
a variable or constant region of a heavy or light chain, a single
chain variable fragment (scFv), or an Fc, Fab, or F(ab).sub.2'
fragment of an antibody, etc. The polypeptide chain of an antibody,
or portion thereof, can exist as a separate polypeptide of the
recombinant antibody. Alternatively, the polypeptide chain of an
antibody, or portion thereof, can exist as a polypeptide, which is
expressed in frame (in tandem) with the polypeptide of the
invention. The polypeptide of an antibody, or portion thereof, can
be a polypeptide of any antibody or any antibody fragment,
including any of the antibodies and antibody fragments described
herein.
Included in the scope of the invention are functional variants of
the inventive TCRs, polypeptides, and proteins described herein.
The term "functional variant" as used herein refers to a TCR,
polypeptide, or protein having substantial or significant sequence
identity or similarity to a parent TCR, polypeptide, or protein,
which functional variant retains the biological activity of the
TCR, polypeptide, or protein of which it is a variant. Functional
variants encompass, for example, those variants of the TCR,
polypeptide, or protein described herein (the parent TCR,
polypeptide, or protein) that retain the ability to specifically
bind to SSX-2 for which the parent TCR has antigenic specificity or
to which the parent polypeptide or protein specifically binds, to a
similar extent, the same extent, or to a higher extent, as the
parent TCR, polypeptide, or protein. Alternatively or additionally,
functional variants can also encompass, for example, those variants
of the TCR, polypeptide, or protein described herein (the parent
TCR, polypeptide, or protein) that retain the ability to recognize
any one or more of SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10, which
the parent polypeptide or protein recognizes, to a similar extent,
the same extent, or to a higher extent, as the parent TCR,
polypeptide, or protein. In reference to the parent TCR,
polypeptide, or protein, the functional variant can, for instance,
be at least about 30%, 50%, 75%, 80%, 90%, 95%, 96%, 97%, 98%, 99%
or more identical in amino acid sequence to the parent TCR,
polypeptide, or protein.
The functional variant can, for example, comprise the amino acid
sequence of the parent TCR, polypeptide, or protein with at least
one conservative amino acid substitution. Conservative amino acid
substitutions are known in the art, and include amino acid
substitutions in which one amino acid having certain physical
and/or chemical properties is exchanged for another amino acid that
has the same chemical or physical properties. For instance, the
conservative amino acid substitution can be an acidic amino acid
substituted for another acidic amino acid (e.g., Asp or Glu), an
amino acid with a nonpolar side chain substituted for another amino
acid with a nonpolar side chain (e.g., Ala, Gly, Val, Ile, Leu,
Met, Phe, Pro, Trp, Val, etc.), a basic amino acid substituted for
another basic amino acid (Lys, Arg, etc.), an amino acid with a
polar side chain substituted for another amino acid with a polar
side chain (Asn, Cys, Gln, Ser, Thr, Tyr, etc.), etc.
Alternatively or additionally, the functional variants can comprise
the amino acid sequence of the parent TCR, polypeptide, or protein
with at least one non-conservative amino acid substitution. In this
case, it is preferable for the non-conservative amino acid
substitution to not interfere with or inhibit the biological
activity of the functional variant. Preferably, the
non-conservative amino acid substitution enhances the biological
activity of the functional variant, such that the biological
activity of the functional variant is increased as compared to the
parent TCR, polypeptide, or protein.
The TCR, polypeptide, or protein can consist essentially of the
specified amino acid sequence or sequences described herein, such
that other components of the functional variant, e.g., other amino
acids, do not materially change the biological activity of the
functional variant. In this regard, the inventive TCR, polypeptide,
or protein can, for example, consist essentially of the amino acid
sequence of SEQ ID NO: 23, 24, 25, 26, both SEQ ID NOs: 23 and 24,
or both SEQ ID NOs: 25 and 26. Also, for instance, the inventive
TCRs, polypeptides, or proteins can consist essentially of the
amino acid sequence(s) of SEQ ID NO: 19, 20, 21, 22, 35, 36, both
SEQ ID NOs: 19 and 20, both SEQ ID NOs: 21 and 22, or both SEQ ID
NOs: 35 and 36. Furthermore, the inventive TCRs, polypeptides, or
proteins can consist essentially of the amino acid sequence of SEQ
ID NO: 13 (CDR1 of .alpha. chain), 14 (CDR2 of .alpha. chain), 15
(CDR3 of .alpha. chain), 16 (CDR1 of .beta. chain), 17 (CDR2 of
.beta. chain), 18 (CDR3 of .beta. chain), or any combination
thereof, e.g., SEQ ID NOs: 13-15, 16-18, or 13-18.
The TCRs, polypeptides, and proteins of the invention (including
functional portions and functional variants) can be of any length,
i.e., can comprise any number of amino acids, provided that the
TCRs, polypeptides, or proteins (or functional portions or
functional variants thereof) retain their biological activity,
e.g., the ability to specifically bind to SSX-2; recognize any one
or more of SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10; detect cancer in
a host; or treat or prevent cancer in a host, etc. For example, the
polypeptide can be 50 to 5000 amino acids long, such as 50, 70, 75,
100, 125, 150, 175, 200, 300, 400, 500, 600, 700, 800, 900, 1000 or
more amino acids in length. In this regard, the polypeptides of the
invention also include oligopeptides.
The TCRs, polypeptides, and proteins of the invention (including
functional portions and functional variants) of the invention can
comprise synthetic amino acids in place of one or more
naturally-occurring amino acids. Such synthetic amino acids are
known in the art, and include, for example, aminocyclohexane
carboxylic acid, norleucine, .alpha.-amino n-decanoic acid,
homoserine, S-acetylaminomethyl-cysteine, trans-3- and
trans-4-hydroxyproline, 4-aminophenylalanine, 4-nitrophenylalanine,
4-chlorophenylalanine, 4-carboxyphenylalanine, .beta.-phenylserine
.beta.-hydroxyphenylalanine, phenylglycine,
.alpha.-naphthylalanine, cyclohexylalanine, cyclohexylglycine,
indoline-2-carboxylic acid,
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomalonic
acid, aminomalonic acid monoamide, N'-benzyl-N'-methyl-lysine,
N',N'-dibenzyl-lysine, 6-hydroxylysine, ornithine,
.alpha.-aminocyclopentane carboxylic acid, .alpha.-aminocyclohexane
carboxylic acid, .alpha.-aminocycloheptane carboxylic acid,
.alpha.-(2-amino-2-norbornane)-carboxylic acid,
.alpha.,.gamma.-diaminobutyric acid,
.alpha.,.beta.-diaminopropionic acid, homophenylalanine, and
.alpha.-tert-butylglycine.
The TCRs, polypeptides, and proteins of the invention (including
functional portions and functional variants) can be glycosylated,
amidated, carboxylated, phosphorylated, esterified, N-acylated,
cyclized via, e.g., a disulfide bridge, or converted into an acid
addition salt and/or optionally dimerized or polymerized, or
conjugated.
When the TCRs, polypeptides, and proteins of the invention
(including functional portions and functional variants) are in the
form of a salt, preferably, the polypeptides are in the form of a
pharmaceutically acceptable salt. Suitable pharmaceutically
acceptable acid addition salts include those derived from mineral
acids, such as hydrochloric, hydrobromic, phosphoric,
metaphosphoric, nitric, and sulphuric acids, and organic acids,
such as tartaric, acetic, citric, malic, lactic, fumaric, benzoic,
glycolic, gluconic, succinic, and arylsulphonic acids, for example,
p-toluenesulphonic acid.
The TCR, polypeptide, and/or protein of the invention (including
functional portions and functional variants thereof) can be
obtained by methods known in the art. Suitable methods of de novo
synthesizing polypeptides and proteins are described in references,
such as Chan et al., Fmoc Solid Phase Peptide Synthesis, Oxford
University Press, Oxford, United Kingdom, 2005; Peptide and Protein
Drug Analysis, ed. Reid, R., Marcel Dekker, Inc., 2000; Epitope
Mapping, ed. Westwood et al., Oxford University Press, Oxford,
United Kingdom, 2000; and U.S. Pat. No. 5,449,752. Also,
polypeptides and proteins can be recombinantly produced using the
nucleic acids described herein using standard recombinant methods.
See, for instance, Sambrook et al., Molecular Cloning: A Laboratory
Manual, 3.sup.rd ed., Cold Spring Harbor Press, Cold Spring Harbor,
N.Y. 2001; and Ausubel et al., Current Protocols in Molecular
Biology, Greene Publishing Associates and John Wiley & Sons, N
Y, 1994. Further, some of the TCRs, polypeptides, and proteins of
the invention (including functional portions and functional
variants thereof) can be isolated and/or purified from a source,
such as a plant, a bacterium, an insect, a mammal, e.g., a rat, a
human, etc. Methods of isolation and purification are well-known in
the art. Alternatively, the TCRs, polypeptides, and/or proteins
described herein (including functional portions and functional
variants thereof) can be commercially synthesized by companies,
such as Synpep (Dublin, Calif.), Peptide Technologies Corp.
(Gaithersburg, Md.), and Multiple Peptide Systems (San Diego,
Calif.). In this respect, the inventive TCRs, polypeptides, and
proteins can be synthetic, recombinant, isolated, and/or
purified.
Included in the scope of the invention are conjugates, e.g.,
bioconjugates, comprising any of the inventive TCRs, polypeptides,
or proteins (including any of the functional portions or variants
thereof), nucleic acids, recombinant expression vectors, host
cells, populations of host cells, or antibodies, or antigen binding
portions thereof. Conjugates, as well as methods of synthesizing
conjugates in general, are known in the art (See, for instance,
Hudecz, F., Methods Mol. Biol. 298: 209-223 (2005) and Kirin et
al., Inorg Chem. 44(15): 5405-5415 (2005)).
Further provided by the invention is a nucleic acid comprising a
nucleotide sequence encoding any of the TCRs, polypeptides, or
proteins described herein (including functional portions and
functional variants thereof).
By "nucleic acid" as used herein includes "polynucleotide,"
"oligonucleotide," and "nucleic acid molecule," and generally means
a polymer of DNA or RNA, which can be single-stranded or
double-stranded, synthesized or obtained (e.g., isolated and/or
purified) from natural sources, which can contain natural,
non-natural or altered nucleotides, and which can contain a
natural, non-natural or altered internucleotide linkage, such as a
phosphoroamidate linkage or a phosphorothioate linkage, instead of
the phosphodiester found between the nucleotides of an unmodified
oligonucleotide. It is generally preferred that the nucleic acid
does not comprise any insertions, deletions, inversions, and/or
substitutions. However, it may be suitable in some instances, as
discussed herein, for the nucleic acid to comprise one or more
insertions, deletions, inversions, and/or substitutions.
Preferably, the nucleic acids of the invention are recombinant. As
used herein, the term "recombinant" refers to (i) molecules that
are constructed outside living cells by joining natural or
synthetic nucleic acid segments to nucleic acid molecules that can
replicate in a living cell, or (ii) molecules that result from the
replication of those described in (i) above. For purposes herein,
the replication can be in vitro replication or in vivo
replication.
The nucleic acids can be constructed based on chemical synthesis
and/or enzymatic ligation reactions using procedures known in the
art. See, for example, Sambrook et al., supra, and Ausubel et al.,
supra. For example, a nucleic acid can be chemically synthesized
using naturally occurring nucleotides or variously modified
nucleotides designed to increase the biological stability of the
molecules or to increase the physical stability of the duplex
formed upon hybridization (e.g., phosphorothioate derivatives and
acridine substituted nucleotides). Examples of modified nucleotides
that can be used to generate the nucleic acids include, but are not
limited to, 5-fluorouracil, 5-bromouracil, 5-chlorouracil,
5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine,
5-(carboxyhydroxymethyl) uracil,
5-carboxymethylaminomethyl-2-thiouridine,
5-carboxymethylaminomethyluracil, dihydrouracil,
beta-D-galactosylqueosine, inosine, N.sup.6-isopentenyladenine,
1-methyl guanine, 1-methylinosine, 2,2-dimethylguanine,
2-methyladenine, 2-methyl guanine, 3-methylcytosine,
5-methylcytosine, N.sup.6-substituted adenine, 7-methylguanine,
5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil,
beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil,
5-methoxyuracil, 2-methylthio-N.sup.6-isopentenyladenine,
uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine,
2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,
5-methyluracil, uracil-5-oxyacetic acid methylester,
3-(3-amino-3-N-2-carboxypropyl) uracil, and 2,6-diaminopurine.
Alternatively, one or more of the nucleic acids of the invention
can be purchased from companies, such as Macromolecular Resources
(Fort Collins, Colo.) and Synthegen (Houston, Tex.).
The nucleic acid can comprise any nucleotide sequence which encodes
any of the TCRs, polypeptides, or proteins, or functional portions
or functional variants thereof. For example, the nucleic acid can
comprise a nucleotide sequence comprising, consisting of, or
consisting essentially of, SEQ ID NO: 27 (encodes anti-SSX-2 TCR
alpha and beta chains) or SEQ ID NO: 28 (encodes human/mouse
chimeric anti-SSX-2 TCR alpha and beta chains). The nucleotide
sequence alternatively can comprise a nucleotide sequence which is
degenerate to SEQ ID NO: 27 or 28.
In some embodiments, the nucleic acid sequence may be optimized.
Without being bound to a particular theory, it is believed that
optimization of the nucleic acid sequence increases the translation
efficiency of the mRNA transcripts. Optimization of the nucleic
acid sequence may involve substituting a native codon for another
codon that encodes the same amino acid, but can be translated by
tRNA that is more readily available within a cell, thus increasing
translation efficiency. Optimization of the nucleic acid sequence
may also reduce secondary mRNA structures that would interfere with
translation, thus increasing translation efficiency. For example,
the optimized nucleic acid can comprise a nucleotide sequence
comprising, consisting of, or consisting essentially of, SEQ ID NO:
29 (encodes anti-SSX-2 TCR alpha and beta chains) or SEQ ID NO: 30
(encodes human/mouse chimeric anti-SSX-2 TCR alpha and beta
chains). The nucleotide sequence alternatively can comprise a
nucleotide sequence which is degenerate to SEQ ID NO: 29 or 30.
The invention also provides an isolated or purified nucleic acid
comprising a nucleotide sequence which is complementary to the
nucleotide sequence of any of the nucleic acids described herein or
a nucleotide sequence which hybridizes under stringent conditions
to the nucleotide sequence of any of the nucleic acids described
herein.
The nucleotide sequence which hybridizes under stringent conditions
preferably hybridizes under high stringency conditions. By "high
stringency conditions" is meant that the nucleotide sequence
specifically hybridizes to a target sequence (the nucleotide
sequence of any of the nucleic acids described herein) in an amount
that is detectably stronger than non-specific hybridization. High
stringency conditions include conditions which would distinguish a
polynucleotide with an exact complementary sequence, or one
containing only a few scattered mismatches from a random sequence
that happened to have a few small regions (e.g., 3-10 bases) that
matched the nucleotide sequence. Such small regions of
complementarity are more easily melted than a full-length
complement of 14-17 or more bases, and high stringency
hybridization makes them easily distinguishable. Relatively high
stringency conditions would include, for example, low salt and/or
high temperature conditions, such as provided by about 0.02-0.1 M
NaCl or the equivalent, at temperatures of about 50-70.degree. C.
Such high stringency conditions tolerate little, if any, mismatch
between the nucleotide sequence and the template or target strand,
and are particularly suitable for detecting expression of any of
the inventive TCRs. It is generally appreciated that conditions can
be rendered more stringent by the addition of increasing amounts of
formamide.
The nucleic acids of the invention can be incorporated into a
recombinant expression vector. In this regard, the invention
provides recombinant expression vectors comprising any of the
nucleic acids of the invention. For purposes herein, the term
"recombinant expression vector" means a genetically-modified
oligonucleotide or polynucleotide construct that permits the
expression of an mRNA, protein, polypeptide, or peptide by a host
cell, when the construct comprises a nucleotide sequence encoding
the mRNA, protein, polypeptide, or peptide, and the vector is
contacted with the cell under conditions sufficient to have the
mRNA, protein, polypeptide, or peptide expressed within the cell.
The vectors of the invention are not naturally-occurring as a
whole. However, parts of the vectors can be naturally-occurring.
The inventive recombinant expression vectors can comprise any type
of nucleotides, including, but not limited to DNA and RNA, which
can be single-stranded or double-stranded, synthesized or obtained
in part from natural sources, and which can contain natural,
non-natural or altered nucleotides. The recombinant expression
vectors can comprise naturally-occurring, non-naturally-occurring
intemucleotide linkages, or both types of linkages. Preferably, the
non-naturally occurring or altered nucleotides or intemucleotide
linkages does not hinder the transcription or replication of the
vector.
The recombinant expression vector of the invention can be any
suitable recombinant expression vector, and can be used to
transform or transfect any suitable host. Suitable vectors include
those designed for propagation and expansion or for expression or
both, such as plasmids and viruses. The vector can be selected from
the group consisting of the pUC series (Fennentas Life Sciences),
the pBluescript series (Stratagene, LaJolla, Calif.), the pET
series (Novagen, Madison, Wis.), the pGEX series (Pharmacia
Biotech, Uppsala, Sweden), and the pEX series (Clontech, Palo Alto,
Calif.). Bacteriophage vectors, such as .lamda.GT10, .lamda.GT11,
.lamda.ZapII (Stratagene), .lamda.EMBL4, and .lamda.NM1149, also
can be used. Examples of plant expression vectors include pBI01,
pBI101.2, pBI101.3, pBI121 and pBIN19 (Clontech). Examples of
animal expression vectors include pEUK-C1, pMAM and pMAMneo
(Clontech). Preferably, the recombinant expression vector is a
viral vector, e.g., a retroviral vector.
The recombinant expression vectors of the invention can be prepared
using standard recombinant DNA techniques described in, for
example, Sambrook et al., supra, and Ausubel et al., supra.
Constructs of expression vectors, which are circular or linear, can
be prepared to contain a replication system functional in a
prokaryotic or eukaryotic host cell. Replication systems can be
derived, e.g., from ColE1, 2.mu. plasmid, .lamda., SV40, bovine
papilloma virus, and the like.
Desirably, the recombinant expression vector comprises regulatory
sequences, such as transcription and translation initiation and
termination codons, which are specific to the type of host (e.g.,
bacterium, fungus, plant, or animal) into which the vector is to be
introduced, as appropriate and taking into consideration whether
the vector is DNA- or RNA-based.
The recombinant expression vector can include one or more marker
genes, which allow for selection of transformed or transfected
hosts. Marker genes include biocide resistance, e.g., resistance to
antibiotics, heavy metals, etc., complementation in an auxotrophic
host to provide prototrophy, and the like. Suitable marker genes
for the inventive expression vectors include, for instance,
neomycin/G418 resistance genes, hygromycin resistance genes,
histidinol resistance genes, tetracycline resistance genes, and
ampicillin resistance genes.
The recombinant expression vector can comprise a native or
nonnative promoter operably linked to the nucleotide sequence
encoding the TCR, polypeptide, or protein (including functional
portions and functional variants thereof), or to the nucleotide
sequence which is complementary to or which hybridizes to the
nucleotide sequence encoding the TCR, polypeptide, or protein. The
selection of promoters, e.g., strong, weak, inducible,
tissue-specific and developmental-specific, is within the ordinary
skill of the artisan. Similarly, the combining of a nucleotide
sequence with a promoter is also within the skill of the artisan.
The promoter can be a non-viral promoter or a viral promoter, e.g.,
a cytomegalovirus (CMV) promoter, an SV40 promoter, an RSV
promoter, and a promoter found in the long-terminal repeat of the
murine stem cell virus.
The inventive recombinant expression vectors can be designed for
either transient expression, for stable expression, or for both.
Also, the recombinant expression vectors can be made for
constitutive expression or for inducible expression. Further, the
recombinant expression vectors can be made to include a suicide
gene.
As used herein, the term "suicide gene" refers to a gene that
causes the cell expressing the suicide gene to die. The suicide
gene can be a gene that confers sensitivity to an agent, e.g., a
drug, upon the cell in which the gene is expressed, and causes the
cell to die when the cell is contacted with or exposed to the
agent. Suicide genes are known in the art (see, for example,
Suicide Gene Therapy: Methods and Reviews, Springer, Caroline J.
(Cancer Research UK Centre for Cancer Therapeutics at the Institute
of Cancer Research, Sutton, Surrey, UK), Humana Press, 2004) and
include, for example, the Herpes Simplex Virus (HSV) thymidine
kinase (TK) gene, cytosine daminase, purine nucleoside
phosphorylase, and nitroreductase.
Another embodiment of the invention further provides a host cell
comprising any of the recombinant expression vectors described
herein. As used herein, the term "host cell" refers to any type of
cell that can contain the inventive recombinant expression vector.
The host cell can be a eukaryotic cell, e.g., plant, animal, fungi,
or algae, or can be a prokaryotic cell, e.g., bacteria or protozoa.
The host cell can be a cultured cell or a primary cell, i.e.,
isolated directly from an organism, e.g., a human. The host cell
can be an adherent cell or a suspended cell, i.e., a cell that
grows in suspension. Suitable host cells are known in the art and
include, for instance, DH5a E. coli cells, Chinese hamster ovarian
cells, monkey VERO cells, COS cells, HEK293 cells, and the like.
For purposes of amplifying or replicating the recombinant
expression vector, the host cell is preferably a prokaryotic cell,
e.g., a DH5.alpha. cell. For purposes of producing a recombinant
TCR, polypeptide, or protein, the host cell is preferably a
mammalian cell. Most preferably, the host cell is a human cell.
While the host cell can be of any cell type, can originate from any
type of tissue, and can be of any developmental stage, the host
cell preferably is a peripheral blood leukocyte (PBL) or a
peripheral blood mononuclear cell (PBMC). More preferably, the host
cell is a T cell.
For purposes herein, the T cell can be any T cell, such as a
cultured T cell, e.g., a primary T cell, or a T cell from a
cultured T cell line, e.g., Jurkat, SupT1, etc., or a T cell
obtained from a mammal. If obtained from a mammal, the T cell can
be obtained from numerous sources, including but not limited to
blood, bone marrow, lymph node, the thymus, or other tissues or
fluids. T cells can also be enriched for or purified. Preferably,
the T cell is a human T cell. More preferably, the T cell is a T
cell isolated from a human. The T cell can be any type of T cell
and can be of any developmental stage, including but not limited
to, CD4.sup.+/CD8.sup.+ double positive T cells, CD4.sup.+ helper T
cells, e.g., Th.sub.1 and Th.sub.2 cells, CD8.sup.+ T cells (e.g.,
cytotoxic T cells), tumor infiltrating cells (TILs), memory T
cells, naive T cells, and the like. Preferably, the T cell is a
CD8.sup.+ T cell or a CD4.sup.+ T cell.
Also provided by the invention is a population of cells comprising
at least one host cell described herein. The population of cells
can be a heterogeneous population comprising the host cell
comprising any of the recombinant expression vectors described, in
addition to at least one other cell, e.g., a host cell (e.g., a T
cell), which does not comprise any of the recombinant expression
vectors, or a cell other than a T cell, e.g., a B cell, a
macrophage, a neutrophil, an erythrocyte, a hepatocyte, an
endothelial cell, an epithelial cells, a muscle cell, a brain cell,
etc. Alternatively, the population of cells can be a substantially
homogeneous population, in which the population comprises mainly of
host cells (e.g., consisting essentially of) comprising the
recombinant expression vector. The population also can be a clonal
population of cells, in which all cells of the population are
clones of a single host cell comprising a recombinant expression
vector, such that all cells of the population comprise the
recombinant expression vector. In one embodiment of the invention,
the population of cells is a clonal population comprising host
cells comprising a recombinant expression vector as described
herein.
The invention further provides an antibody, or antigen binding
portion thereof, which specifically binds to a functional portion
of any of the TCRs described herein. Preferably, the functional
portion specifically binds to the cancer antigen, e.g., the
functional portion comprising the amino acid sequence SEQ ID NO: 13
(CDR1 of .alpha. chain), 14 (CDR2 of .alpha. chain), 15 (CDR3 of
.alpha. chain), 16 (CDR1 of .beta. chain), 17 (CDR2 of .beta.
chain), 18 (CDR3 of .beta. chain), SEQ ID NO: 19, SEQ ID NO: 20,
SEQ ID NO: 35, SEQ ID NO: 36, or a combination thereof, e.g.,
13-15; 16-18; 13-18; 19-20, or 35-36. More preferably, the
functional portion comprises the amino acid sequences of SEQ ID
NOs: 13-18. In a preferred embodiment, the antibody, or antigen
binding portion thereof, binds to an epitope which is formed by all
6 CDRs (CDR1-3 of the alpha chain and CDR1-3 of the beta chain).
The antibody can be any type of immunoglobulin that is known in the
art. For instance, the antibody can be of any isotype, e.g., IgA,
IgD, IgE, IgG, IgM, etc. The antibody can be monoclonal or
polyclonal. The antibody can be a naturally-occurring antibody,
e.g., an antibody isolated and/or purified from a mammal, e.g.,
mouse, rabbit, goat, horse, chicken, hamster, human, etc.
Alternatively, the antibody can be a genetically-engineered
antibody, e.g., a humanized antibody or a chimeric antibody. The
antibody can be in monomeric or polymeric form. Also, the antibody
can have any level of affinity or avidity for the functional
portion of the inventive TCR. Desirably, the antibody is specific
for the functional portion of the inventive TCR, such that there is
minimal cross-reaction with other peptides or proteins.
Methods of testing antibodies for the ability to bind to any
functional portion of the inventive TCR are known in the art and
include any antibody-antigen binding assay, such as, for example,
radioimmunoassay (RIA), ELISA, Western blot, immunoprecipitation,
and competitive inhibition assays (see, e.g., Janeway et al.,
infra, and U.S. Patent Application Publication No. 2002/0197266
A1).
Suitable methods of making antibodies are known in the art. For
instance, standard hybridoma methods are described in, e.g., Kohler
and Milstein, Eur. J. Immunol., 5, 511-519 (1976), Harlow and Lane
(eds.), Antibodies: A Laboratory Manual, CSH Press (1988), and C.
A. Janeway et al. (eds.), Immunobiology, 5.sup.th Ed., Garland
Publishing, New York, N.Y. (2001)). Alternatively, other methods,
such as EBV-hybridoma methods (Haskard and Archer, J. Immunol.
Methods, 74(2), 361-67 (1984), and Roder et al., Methods Enzymol.,
121, 140-67 (1986)), and bacteriophage vector expression systems
(see, e.g., Huse et al., Science, 246, 1275-81 (1989)) are known in
the art. Further, methods of producing antibodies in non-human
animals are described in, e.g., U.S. Pat. Nos. 5,545,806,
5,569,825, and 5,714,352, and U.S. Patent Application Publication
No. 2002/0197266 A1).
Phage display furthermore can be used to generate the antibody of
the invention. In this regard, phage libraries encoding
antigen-binding variable (V) domains of antibodies can be generated
using standard molecular biology and recombinant DNA techniques
(see, e.g., Sambrook et al. (eds.), Molecular Cloning, A Laboratory
Manual, 3.sup.rd Edition, Cold Spring Harbor Laboratory Press, New
York (2001)). Phage encoding a variable region with the desired
specificity are selected for specific binding to the desired
antigen, and a complete or partial antibody is reconstituted
comprising the selected variable domain. Nucleic acid sequences
encoding the reconstituted antibody are introduced into a suitable
cell line, such as a myeloma cell used for hybridoma production,
such that antibodies having the characteristics of monoclonal
antibodies are secreted by the cell (see, e.g., Janeway et al.,
supra, Huse et al., supra, and U.S. Pat. No. 6,265,150).
Antibodies can be produced by transgenic mice that are transgenic
for specific heavy and light chain immunoglobulin genes. Such
methods are known in the art and described in, for example U.S.
Pat. Nos. 5,545,806 and 5,569,825, and Janeway et al., supra.
Methods for generating humanized antibodies are well known in the
art and are described in detail in, for example, Janeway et al.,
supra, U.S. Pat. Nos. 5,225,539, 5,585,089 and 5,693,761, European
Patent No. 0239400 B1, and United Kingdom Patent No. 2188638.
Humanized antibodies can also be generated using the antibody
resurfacing technology described in U.S. Pat. No. 5,639,641 and
Pedersen et al., J. Mol. Biol., 235, 959-973 (1994).
The invention also provides antigen binding portions of any of the
antibodies described herein. The antigen binding portion can be any
portion that has at least one antigen binding site, such as Fab,
F(ab').sub.2, dsFv, sFv, diabodies, and triabodies.
A single-chain variable region fragment (sFv) antibody fragment,
which consists of a truncated Fab fragment comprising the variable
(V) domain of an antibody heavy chain linked to a V domain of a
light antibody chain via a synthetic peptide, can be generated
using routine recombinant DNA technology techniques (see, e.g.,
Janeway et al., supra). Similarly, disulfide-stabilized variable
region fragments (dsFv) can be prepared by recombinant DNA
technology (see, e.g., Reiter et al., Protein Engineering, 7,
697-704 (1994)). Antibody fragments of the invention, however, are
not limited to these exemplary types of antibody fragments.
Also, the antibody, or antigen binding portion thereof, can be
modified to comprise a detectable label, such as, for instance, a
radioisotope, a fluorophore (e.g., fluorescein isothiocyanate
(FITC), phycoerythrin (PE)), an enzyme (e.g., alkaline phosphatase,
horseradish peroxidase), and element particles (e.g., gold
particles).
The inventive TCRs, polypeptides, proteins, (including functional
portions and functional variants thereof), nucleic acids,
recombinant expression vectors, host cells (including populations
thereof), and antibodies (including antigen binding portions
thereof), can be isolated and/or purified. The term "isolated" as
used herein means having been removed from its natural environment.
The term "purified" as used herein means having been increased in
purity, wherein "purity" is a relative term, and not to be
necessarily construed as absolute purity. For example, the purity
can be at least about 50%, can be greater than 60%, 70% or 80%, 90%
or can be 100%.
The inventive TCRs, polypeptides, proteins (including functional
portions and variants thereof), nucleic acids, recombinant
expression vectors, host cells (including populations thereof), and
antibodies (including antigen binding portions thereof), all of
which are collectively referred to as "inventive TCR materials"
hereinafter, can be formulated into a composition, such as a
pharmaceutical composition. In this regard, the invention provides
a pharmaceutical composition comprising any of the TCRs,
polypeptides, proteins, functional portions, functional variants,
nucleic acids, expression vectors, host cells (including
populations thereof), and antibodies (including antigen binding
portions thereof), and a pharmaceutically acceptable carrier. The
inventive pharmaceutical compositions containing any of the
inventive TCR materials can comprise more than one inventive TCR
material, e.g., a polypeptide and a nucleic acid, or two or more
different TCRs. Alternatively, the pharmaceutical composition can
comprise an inventive TCR material in combination with another
pharmaceutically active agents or drugs, such as a chemotherapeutic
agents, e.g., asparaginase, busulfan, carboplatin, cisplatin,
daunorubicin, doxorubicin, fluorouracil, gemcitabine, hydroxyurea,
methotrexate, paclitaxel, rituximab, vinblastine, vincristine,
etc.
Preferably, the carrier is a pharmaceutically acceptable carrier.
With respect to pharmaceutical compositions, the carrier can be any
of those conventionally used and is limited only by
chemico-physical considerations, such as solubility and lack of
reactivity with the active compound(s), and by the route of
administration. The pharmaceutically acceptable carriers described
herein, for example, vehicles, adjuvants, excipients, and diluents,
are well-known to those skilled in the art and are readily
available to the public. It is preferred that the pharmaceutically
acceptable carrier be one which is chemically inert to the active
agent(s) and one which has no detrimental side effects or toxicity
under the conditions of use.
The choice of carrier will be determined in part by the particular
inventive TCR material, as well as by the particular method used to
administer the inventive TCR material. Accordingly, there are a
variety of suitable formulations of the pharmaceutical composition
of the invention. The following formulations for oral, aerosol,
parenteral, subcutaneous, intravenous, intramuscular,
intraarterial, intrathecal, and interperitoneal administration are
exemplary and are in no way limiting. More than one route can be
used to administer the inventive TCR materials, and in certain
instances, a particular route can provide a more immediate and more
effective response than another route.
Topical formulations are well-known to those of skill in the art.
Such formulations are particularly suitable in the context of the
invention for application to the skin.
Formulations suitable for oral administration can consist of (a)
liquid solutions, such as an effective amount of the inventive TCR
material dissolved in diluents, such as water, saline, or orange
juice; (b) capsules, sachets, tablets, lozenges, and troches, each
containing a predetermined amount of the active ingredient, as
solids or granules; (c) powders; (d) suspensions in an appropriate
liquid; and (e) suitable emulsions. Liquid formulations may include
diluents, such as water and alcohols, for example, ethanol, benzyl
alcohol, and the polyethylene alcohols, either with or without the
addition of a pharmaceutically acceptable surfactant. Capsule forms
can be of the ordinary hard- or soft-shelled gelatin type
containing, for example, surfactants, lubricants, and inert
fillers, such as lactose, sucrose, calcium phosphate, and corn
starch. Tablet forms can include one or more of lactose, sucrose,
mannitol, corn starch, potato starch, alginic acid,
microcrystalline cellulose, acacia, gelatin, guar gum, colloidal
silicon dioxide, croscarmellose sodium, talc, magnesium stearate,
calcium stearate, zinc stearate, stearic acid, and other
excipients, colorants, diluents, buffering agents, disintegrating
agents, moistening agents, preservatives, flavoring agents, and
other pharmacologically compatible excipients. Lozenge forms can
comprise the inventive TCR material in a flavor, usually sucrose
and acacia or tragacanth, as well as pastilles comprising the
inventive TCR material in an inert base, such as gelatin and
glycerin, or sucrose and acacia, emulsions, gels, and the like
containing, in addition to, such excipients as are known in the
art.
The inventive TCR material, alone or in combination with other
suitable components, can be made into aerosol formulations to be
administered via inhalation. These aerosol formulations can be
placed into pressurized acceptable propellants, such as
dichlorodifluoromethane, propane, nitrogen, and the like. They also
may be formulated as pharmaceuticals for non-pressured
preparations, such as in a nebulizer or an atomizer. Such spray
formulations also may be used to spray mucosa.
Formulations suitable for parenteral administration include aqueous
and non-aqueous, isotonic sterile injection solutions, which can
contain anti-oxidants, buffers, bacteriostats, and solutes that
render the formulation isotonic with the blood of the intended
recipient, and aqueous and non-aqueous sterile suspensions that can
include suspending agents, solubilizers, thickening agents,
stabilizers, and preservatives. The inventive TCR material can be
administered in a physiologically acceptable diluent in a
pharmaceutical carrier, such as a sterile liquid or mixture of
liquids, including water, saline, aqueous dextrose and related
sugar solutions, an alcohol, such as ethanol or hexadecyl alcohol,
a glycol, such as propylene glycol or polyethylene glycol,
dimethylsulfoxide, glycerol, ketals such as
2,2-dimethyl-1,3-dioxolane-4-methanol, ethers, poly(ethyleneglycol)
400, oils, fatty acids, fatty acid esters or glycerides, or
acetylated fatty acid glycerides with or without the addition of a
pharmaceutically acceptable surfactant, such as a soap or a
detergent, suspending agent, such as pectin, carbomers,
methylcellulose, hydroxypropylmethylcellulose, or
carboxymethylcellulose, or emulsifying agents and other
pharmaceutical adjuvants.
Oils, which can be used in parenteral formulations include
petroleum, animal, vegetable, or synthetic oils. Specific examples
of oils include peanut, soybean, sesame, cottonseed, corn, olive,
petrolatum, and mineral. Suitable fatty acids for use in parenteral
formulations include oleic acid, stearic acid, and isostearic acid.
Ethyl oleate and isopropyl myristate are examples of suitable fatty
acid esters.
Suitable soaps for use in parenteral formulations include fatty
alkali metal, ammonium, and triethanolamine salts, and suitable
detergents include (a) cationic detergents such as, for example,
dimethyl dialkyl ammonium halides, and alkyl pyridinium halides,
(b) anionic detergents such as, for example, alkyl, aryl, and
olefin sulfonates, alkyl, olefin, ether, and monoglyceride
sulfates, and sulfosuccinates, (c) nonionic detergents such as, for
example, fatty amine oxides, fatty acid alkanolamides, and
polyoxyethylenepolypropylene copolymers, (d) amphoteric detergents
such as, for example, alkyl-.beta.-aminopropionates, and
2-alkyl-imidazoline quaternary ammonium salts, and (e) mixtures
thereof.
The parenteral formulations will typically contain from about 0.5%
to about 25% by weight of the inventive TCR material in solution.
Preservatives and buffers may be used. In order to minimize or
eliminate irritation at the site of injection, such compositions
may contain one or more nonionic surfactants having a
hydrophile-lipophile balance (HLB) of from about 12 to about 17.
The quantity of surfactant in such formulations will typically
range from about 5% to about 15% by weight. Suitable surfactants
include polyethylene glycol sorbitan fatty acid esters, such as
sorbitan monooleate and the high molecular weight adducts of
ethylene oxide with a hydrophobic base, formed by the condensation
of propylene oxide with propylene glycol. The parenteral
formulations can be presented in unit-dose or multi-dose sealed
containers, such as ampoules and vials, and can be stored in a
freeze-dried (lyophilized) condition requiring only the addition of
the sterile liquid excipient, for example, water, for injections,
immediately prior to use. Extemporaneous injection solutions and
suspensions can be prepared from sterile powders, granules, and
tablets of the kind previously described.
Injectable formulations are in accordance with the invention. The
requirements for effective pharmaceutical carriers for injectable
compositions are well-known to those of ordinary skill in the art
(see, e.g., Pharmaceutics and Pharmacy Practice, J. B. Lippincott
Company, Philadelphia, Pa., Banker and Chalmers, eds., pages
238-250 (1982), and ASHP Handbook on Injectable Drugs, Toissel, 4th
ed., pages 622-630 (1986)). Preferably, when administering cells,
e.g., T cells, the cells are administered via injection.
It will be appreciated by one of skill in the art that, in addition
to the above-described pharmaceutical compositions, the inventive
TCR materials of the invention can be formulated as inclusion
complexes, such as cyclodextrin inclusion complexes, or
liposomes.
For purposes of the invention, the amount or dose of the inventive
TCR material administered should be sufficient to effect, e.g., a
therapeutic or prophylactic response, in the subject or animal over
a reasonable time frame. For example, the dose of the inventive TCR
material should be sufficient to bind to a cancer antigen, or
detect, treat or prevent cancer in a period of from about 2 hours
or longer, e.g., 12 to 24 or more hours, from the time of
administration. In certain embodiments, the time period could be
even longer. The dose will be determined by the efficacy of the
particular inventive TCR material and the condition of the animal
(e.g., human), as well as the body weight of the animal (e.g.,
human) to be treated.
Many assays for determining an administered dose are known in the
art. For purposes of the invention, an assay, which comprises
comparing the extent to which target cells are lysed or IFN-.gamma.
is secreted by T cells expressing the inventive TCR, polypeptide,
or protein upon administration of a given dose of such T cells to a
mammal among a set of mammals of which is each given a different
dose of the T cells, could be used to determine a starting dose to
be administered to a mammal. The extent to which target cells are
lysed or IFN-.gamma. is secreted upon administration of a certain
dose can be assayed by methods known in the art.
The dose of the inventive TCR material also will be determined by
the existence, nature and extent of any adverse side effects that
might accompany the administration of a particular inventive TCR
material. Typically, the attending physician will decide the dosage
of the inventive TCR material with which to treat each individual
patient, taking into consideration a variety of factors, such as
age, body weight, general health, diet, sex, inventive TCR material
to be administered, route of administration, and the severity of
the condition being treated. By way of example and not intending to
limit the invention, the dose of the inventive TCR material can be
about 0.001 to about 1000 mg/kg body weight of the subject being
treated/day, from about 0.01 to about 10 mg/kg body weight/day,
about 0.01 mg to about 1 mg/kg body weight/day.
One of ordinary skill in the art will readily appreciate that the
inventive TCR materials of the invention can be modified in any
number of ways, such that the therapeutic or prophylactic efficacy
of the inventive TCR materials is increased through the
modification. For instance, the inventive TCR materials can be
conjugated either directly or indirectly through a bridge to a
targeting moiety. The practice of conjugating compounds, e.g.,
inventive TCR materials, to targeting moieties is known in the art.
See, for instance, Wadwa et al., J. Drug Targeting 3: 111 (1995)
and U.S. Pat. No. 5,087,616. The term "targeting moiety" as used
herein, refers to any molecule or agent that specifically
recognizes and binds to a cell-surface receptor, such that the
targeting moiety directs the delivery of the inventive TCR
materials to a population of cells on which surface the receptor is
expressed. Targeting moieties include, but are not limited to,
antibodies, or fragments thereof, peptides, hormones, growth
factors, cytokines, and any other natural or non-natural ligands,
which bind to cell surface receptors (e.g., Epithelial Growth
Factor Receptor (EGFR), T-cell receptor (TCR), B-cell receptor
(BCR), CD28, Platelet-derived Growth Factor Receptor (PDGF),
nicotinic acetylcholine receptor (nAChR), etc.). The term "bridge"
as used herein, refers to any agent or molecule that links the
inventive TCR materials to the targeting moiety. One of ordinary
skill in the art recognizes that sites on the inventive TCR
materials, which are not necessary for the function of the
inventive TCR materials, are ideal sites for attaching a bridge
and/or a targeting moiety, provided that the bridge and/or
targeting moiety, once attached to the inventive TCR materials,
do(es) not interfere with the function of the inventive TCR
materials, i.e., the ability to bind to SSX-2; recognize any one or
more of SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10; or to detect,
treat, or prevent cancer.
Alternatively, the inventive TCR materials can be modified into a
depot form, such that the manner in which the inventive TCR
materials is released into the body to which it is administered is
controlled with respect to time and location within the body (see,
for example, U.S. Pat. No. 4,450,150). Depot forms of inventive TCR
materials can be, for example, an implantable composition
comprising the inventive TCR materials and a porous or non-porous
material, such as a polymer, wherein the inventive TCR materials is
encapsulated by or diffused throughout the material and/or
degradation of the non-porous material. The depot is then implanted
into the desired location within the body and the inventive TCR
materials are released from the implant at a predetermined
rate.
In an embodiment of the invention, the pharmaceutical composition
further comprises 5-aza-2'-deoxycytidine (DAC). Without being bound
to a particular theory, it is believed that the demethylating agent
DAC enhances the recognition of cancer cells by any of the
inventive TCR materials by upregulating expression of SSX-2 by
cancer cells.
It is contemplated that the inventive pharmaceutical compositions,
TCRs, polypeptides, proteins, nucleic acids, recombinant expression
vectors, antibodies, host cells, or populations of cells can be
used in methods of treating or preventing cancer. Without being
bound to a particular theory, the inventive TCRs are believed to
bind specifically to SSX-2 and may also recognize any one or more
of SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10, such that the TCR (or
related inventive polypeptide or protein) when expressed by a cell
is able to mediate an immune response against the cell expressing
SSX-2 and may also mediate an immune response against any one or
more of SSX-3, SSX-4, SSX-5, SSX-9, and SSX-10. In this regard, the
invention provides a method of treating or preventing cancer in a
host, comprising administering to the host any of the
pharmaceutical compositions, TCRs, polypeptides, or proteins
described herein, any nucleic acid or recombinant expression vector
comprising a nucleotide sequence encoding any of the TCRs,
polypeptides, proteins described herein, any of the antibodies
described herein, or any host cell or population of cells
comprising a recombinant vector which encodes any of the TCRs,
polypeptides, or proteins described herein, in an amount effective
to treat or prevent cancer in the host.
In an embodiment of the invention, the method of treating or
preventing cancer in a host further comprises administering DAC to
the host. The method may comprise administering DAC prior to,
concurrently with, or after administering any of the inventive
pharmaceutical compositions, TCRs, polypeptides, proteins, nucleic
acids, recombinant expression vectors, host cells, or populations
of cells to the host. Without being bound to a particular theory,
it is believed that the demethylating agent DAC enhances the
recognition of cancer cells by any of the inventive TCR materials
by upregulating expression of SSX-2 by cancer cells.
The terms "treat," and "prevent" as well as words stemming
therefrom, as used herein, do not necessarily imply 100% or
complete treatment or prevention. Rather, there are varying degrees
of treatment or prevention of which one of ordinary skill in the
art recognizes as having a potential benefit or therapeutic effect.
In this respect, the inventive methods can provide any amount of
any level of treatment or prevention of cancer in a mammal.
Furthermore, the treatment or prevention provided by the inventive
method can include treatment or prevention of one or more
conditions or symptoms of the disease, e.g., cancer, being treated
or prevented. Also, for purposes herein, "prevention" can encompass
delaying the onset of the disease, or a symptom or condition
thereof.
Also provided is a method of detecting the presence of cancer in a
host. The method comprises (i) contacting a sample comprising cells
of the cancer any of the inventive TCRs, polypeptides, proteins,
nucleic acids, recombinant expression vectors, host cells,
populations of cells, or antibodies, or antigen binding portions
thereof, described herein, thereby forming a complex, and detecting
the complex, wherein detection of the complex is indicative of the
presence of cancer in the host.
With respect to the inventive method of detecting cancer in a host,
the sample of cells of the cancer can be a sample comprising whole
cells, lysates thereof, or a fraction of the whole cell lysates,
e.g., a nuclear or cytoplasmic fraction, a whole protein fraction,
or a nucleic acid fraction.
For purposes of the inventive detecting method, the contacting step
can take place in vitro or in vivo with respect to the host.
Preferably, the contacting is in vitro.
Also, detection of the complex can occur through any number of ways
known in the art. For instance, the inventive TCRs, polypeptides,
proteins, nucleic acids, recombinant expression vectors, host
cells, populations of cells, or antibodies, or antigen binding
portions thereof, described herein, can be labeled with a
detectable label such as, for instance, a radioisotope, a
fluorophore (e.g., fluorescein isothiocyanate (FITC), phycoerythrin
(PE)), an enzyme (e.g., alkaline phosphatase, horseradish
peroxidase), and element particles (e.g., gold particles).
For purposes of the inventive methods, wherein host cells or
populations of cells are administered, the cells can be cells that
are allogeneic or autologous to the host. Preferably, the cells are
autologous to the host.
With respect to the inventive methods, the cancer can be any
cancer, including any of sarcomas (e.g., synovial sarcoma,
osteogenic sarcoma, leiomyosarcoma uteri, and alveolar
rhabdomyosarcoma), lymphomas (e.g., Hodgkin lymphoma and
non-Hodgkin lymphoma), hepatocellular carcinoma, glioma, head-neck
cancer, acute lymphocytic cancer, acute myeloid leukemia, bone
cancer, brain cancer, breast cancer, cancer of the anus, anal
canal, or anorectum, cancer of the eye, cancer of the intrahepatic
bile duct, cancer of the joints, cancer of the neck, gallbladder,
or pleura, cancer of the nose, nasal cavity, or middle ear, cancer
of the oral cavity, cancer of the vulva, chronic lymphocytic
leukemia, chronic myeloid cancer, colon cancer (e.g., colon
carcinoma), esophageal cancer, cervical cancer, gastrointestinal
carcinoid tumor, hypopharynx cancer, larynx cancer, liver cancer,
lung cancer, malignant mesothelioma, melanoma, multiple myeloma,
nasopharynx cancer, ovarian cancer, pancreatic cancer, peritoneum,
omentum, and mesentery cancer, pharynx cancer, prostate cancer,
rectal cancer, renal cancer, small intestine cancer, soft tissue
cancer, stomach cancer, testicular cancer, thyroid cancer, ureter
cancer, and urinary bladder cancer. Of these, sarcomas (e.g.,
synovial sarcoma, osteogenic sarcoma, leiomyosarcoma uteri, and
alveolar rhabdomyosarcoma), hepatocellular carcinoma, glioma, liver
cancer, melanoma, ovarian cancer, pancreatic cancer, and prostate
cancer are preferably treated.
An embodiment of the invention provides the use of any of the TCRs,
polypeptides, proteins, nucleic acids, recombinant expression
vectors, host cells, populations of cells, antibodies or antigen
binding portions thereof, or pharmaceutical compositions, for the
treatment or prevention of cancer in a host. In an embodiment, the
use may further comprise the use of DAC.
The host referred to in the inventive methods can be any host.
Preferably, the host is a mammal. As used herein, the term "mammal"
refers to any mammal, including, but not limited to, mammals of the
order Rodentia, such as mice and hamsters, and mammals of the order
Logomorpha, such as rabbits. It is preferred that the mammals are
from the order Carnivora, including Felines (cats) and Canines
(dogs). It is more preferred that the mammals are from the order
Artiodactyla, including Bovines (cows) and Swines (pigs) or of the
order Perssodactyla, including Equines (horses). It is most
preferred that the mammals are of the order Primates, Ceboids, or
Simoids (monkeys) or of the order Anthropoids (humans and apes). An
especially preferred mammal is the human.
The following examples further illustrate the invention but should
not be construed as in any way limiting its scope.
Example 1
This example illustrates the construction of a retroviral vector
for expressing SSX-2 and demonstrates SSX-2 expression in certain
cell lines.
The SSX-2 gene was inserted into expression vectors pMSGV1 and
pRRLSIN.cPPT.PGK. The sequence of SSX-2 inserted was:
TABLE-US-00001 (SEQ ID NO: 31)
ATGaacggagacgacgcctttgcaaggagacccacggaggtgctcaaata
ccagagaagatccaaaaggccttcgatgatattgccaaatacttactaag
gaagagtgggaaaagatgaaagcctcggagaaaatcttctatgtgtatat
gaagagaaagtatgaggctatgactaaactaggtttcaaggccaccaccc
acctttcatgtgtaataaacgggccgaagacttccaggggaatgatttgg
ataatgaccctaaccgtgggaatcaggttgaacgtcctcagatgactttc
ggcaggctccagggaatctccccgaagatcatgcccaagaagccagcaga
ggaaggaaatgattcggaggaagtgccagaagcatctggcccacaaaatg
atgggaaagagctgtgccccccgggaaaaccaactacctctgagaagatt
cacgagagatctggaaatagggaggcccaagaaaaggaagagagacgcgg
aacagctcatcggtggagcagtcagaacacacacaacattggtcgattca
gtttgtcaacttctatgggtgcagttcatggtacccccaaaacaattaca
cacaacagggacccaaaaggggggaacatgcctggacccacagactgcgt
gagagaaaacagctggTGA.
The pRRLSIN vector also had WPRE (Woodchuck Hepatitis Virus
Posttranscriptional Regulatory Element) inserted.
Expression of SSX-2 was observed by Western blot in 624.38 cells
and also in COST-A2 cells that were transduced with an SSX2 vector
as above. No SSX-2 expression was observed in H508, Panc2551, A549,
or OVCAR3 cells or non-transduced COST-A2 cells.
SSX-2 was also measured in 938mel, U251, T567A, SKMEL23, and
SKMEL37 cells. The copy number of SSX-2 normalized to .beta.-actin
is shown in Table 1.
TABLE-US-00002 TABLE 1 Copy Number Cell Line SSX-2/10.sup.6
.beta.-actin 938mel 17194.1 U251 6168.2 T567A 8278.0 SKMEL23 0.2
SKMEL37 26568.9
Additional SSX-2 expression studies were performed using real time
PCR. The results are shown in Table 2
TABLE-US-00003 TABLE 2 Tumor Copy Number cell line Histology
SSX-2/10.sup.6 .beta.-actin Capan1 Pancreatic cancer 1447027
CRL1837 Pancreatic cancer 10 Panc1 Pancreatic cancer 255 BxPC3
Pancreatic cancer 1653 Panc2551 Pancreatic cancer 32641 SW1990
Pancreatic cancer 27 MiaPaca2 Pancreatic cancer 212 HPAF-II
Pancreatic cancer 0 H766T Pancreatic cancer 0 HPAC Pancreatic
cancer 0 H508 Colon cancer 5786 HCT116 Colon cancer 0 SW620 Colon
cancer 0 A549 Lung cancer 153 H2087 Lung cancer 54 H1299/A2 Lung
cancer 194 H2126/A2 Lung cancer 204 H446 Lung cancer 550 H596 Lung
cancer 88 H2066 Lung cancer 80 H2122 Lung cancer 0 SKLC17 Lung
cancer 1696 H82 Lung cancer 2303 CALU6 Lung cancer 0 H522 Lung
cancer 1 H358 Lung cancer 0 H446 Lung cancer 4 H1688 Lung cancer nd
H157 Lung cancer 0 H1250 Lung cancer 266 H2721 Lung cancer 75
OvCar3 Ovarian cancer 854 SKOV3 Ovarian cancer 739 MDA-MB-231
Breast cancer 0 MDA468 Breast cancer 0 MCF7 Breast cancer 270 1300
Melanoma 57 1359 Melanoma 1391 586 Melanoma 327 888 Melanoma 137
624.38 Melanoma 915 2984 Melanoma 111 526-NY-ESO Melanoma 0 SKMEL23
Melanoma 1 SKMEL37 Melanoma 18833 T567A Melanoma 7426 T331A
Melanoma 4 [redacted name Renal cancer 193 of cell donor] Toledo
Lymphoma 166 NALM6 Leukemia 0 U251 Glioma 25642 397/A2 10782
SK-N-AS Neuroblastoma 1 PBL Normal 36 lymphocytes 293GP 0
293-SSX2/A2+ 478175 COS7 0 COS-SSX2/A2+ 616981
Example 2
This example illustrates the construction of a retroviral vector
for expressing an SSX-2 specific TCR.
An HLA-A2 restricted TCR from a natural T cell clone was isolated
using 5'-RACE from a tumor-infiltrated lymph node (TILN) from a
melanoma patient seropositive for SSX-2 and whose tumor expressed
SSX-2.
The T cell clone showed: TRAV14/DV4*01 (number of bacterial clones
positive 21/23) and TRBV15*02-CB1 (number of bacterial clones
positive 23/23).
A retroviral vector was constructed expressing the TCR .alpha. and
.beta. chains incorporating the 2a cleavage peptide. Separate PCR
reactions for the .alpha. chain and the .beta. chain were
performed. For the .alpha. chain, the forward primer incorporated
an NcoI restriction site of ATG. The reverse primer had
furin-SGSG-P2a incorporated before the recognition sequence. For
the .beta. chain, the forward primer also incorporated
furin-SGSG-P2a before the recognition sequence, and the reverse
primer had a stop codon and NotI restriction site.
Upon completion, the separate PCR reactions were combined and
additional PCR performed with outside primers to generate an
.alpha. chain (TRAV14)-linker-.beta. chain (TRBV15-CB1) construct.
The construct contained SEQ ID NO: 27, encoding anti-SSX-2 TCR
alpha and beta chains.
The construct was cloned into the pMSGV1 retroviral vector using
the NcoI and NotI restriction sites.
Example 3
This example demonstrates that PBLs engineered with a SSX-2 TCR
show SSX-2 peptide specific reactivity and tetramer binding.
Human donor-derived PBLs were transduced with the SSX-2 TCR vector
of Example 2 and tested for peptide reactivity and tetramer
binding.
Tetramer binding was observed in CD4 and CD8 cells.
SSX-2 TCR-transduced PBLs were co-cultured with T2 cells from two
human donors, where the T2 cells were pulsed with varying
concentrations of the SSX-2: 41-49 (KASEKIFYV) peptide. FIGS. 1A
and 1B show the resulting interferon-.gamma. levels (pg/ml)
measured. These data show that SSX-2 TCR-transduced PBLs recognize
SSX-2: 41-49 peptide down to 0.01 ng/ml, or less. The differences
between FIGS. 1A and 1B may be due to donor variability.
SSX-2 TCR-transduced PBLs were also co-cultured with cells from
Example 1 retroviraily engineered to express the SSX-2 gene. FIG. 2
shows the resulting interferon-.gamma. levels (pg/ml) measured when
the PBLs were co-cultured with 293-A2 and COST-A2 cells expressing
the SSX-2 gene and T2 cells pulsed with the SSX-2: 41-49 peptide.
PBLs that were not transduced with a SSX-2 TCR showed no reactivity
against these cells.
Example 4
This example demonstrates that PBLs engineered with the SSX-2 TCR
of Example 2 show reactivity against tumor cell lines.
SSX-2 TCR-transduced PBLs were co-cultured with various tumor cell
lines. FIG. 3 shows the resulting interferon-.gamma. levels (pg/ml)
measured. These data show that SSX-2 TCR engineered T cells
recognized naturally processed and presented SSX-2 protein in both
melanoma (624, and 1300) and glioblastoma cell lines (U251). PBLs
that were not transduced with a SSX-2 TCR (UT) showed very little
or no reactivity.
FIGS. 4A and 4B, FIG. 11, and Tables 3 and 4 show additional
results of PBLs from human donors that were transduced with the
SSX-2 TCR of Example 2 when these PBLs were co-cultured with
various tumor cells.
TABLE-US-00004 TABLE 3 UT SSX2-TCR IFN-.gamma. IFN-.gamma. Cell
line Histology (pg/ml) (pg/ml) COS-A2 144 297 293-A2 25 173 888 45
126 OVCAR3 0 0 MCF7 0 0 SKMEL 23 0 0 T331A 0 0 COS-A2 SSX2 71 36070
624 Melanoma 0 26515 938-A2 Melanoma 0 19320 938 0 0 293-A2 SSX2 0
33913 U251 Glioma 0 9770 SK MEL37 Melanoma 188 10000 SKOV3 Ovarian
0 663 H82 0 141 HEPG2 0 25 T567A Melanoma 152 10280 MEDIUM 0 0
TABLE-US-00005 TABLE 4 UT SSX2-TCR IFN-.gamma. IFN-.gamma. Cell
line Histology (pg/ml) (pg/ml) COS-A2 280 180 293-A2 112 144 888
115 143 OVCAR3 8 21 MCF7 74 3 SKMEL 23 6 0 T331A 122 42 COS-A2 SSX2
123 56820 624 Melanoma 0 21730 938-A2 Melanoma 38 19192 938 0 0
293-A2 SSX2 125 20595 U251 Glioma 0 12025 SK MEL37 Melanoma 313
9720 SKOV3 Ovarian 93 610 H82 0 100 HEPG2 73 61 T567A Melanoma 382
13245 MEDIUM 25 0
Example 5
This example demonstrates that PBLs engineered with a SSX-2 TCR
show reactivity against other SSX protein peptides.
Co-culture assays were performed with PBLs transduced with the
SSX-2 TCR of Example 2 and peptide-pulsed T2 cells.
FIG. 5 shows the SSX-2 TCR is most reactive with the peptide of
SSX-2 and also recognizes the peptides of SSX-3, -4, -5, -9, and
-10 over the other SSX peptides, although greater recognition is
seen at higher peptide concentrations.
Example 6
This example demonstrates that codon optimization and introduction
of a mouse constant region improved the expression and function of
SSX-2 TCR in human PBLs.
Human PBL were untransduced or transduced with a vector comprising
SEQ ID NO: 27 (SSX-2 TCR), SEQ ID NO: 29 (codon-optimized SSX-2
TCR), or SEQ ID NO: 30 (codon-optimized SSX-2 TCR including mouse
constant region). Expression was measured by FACS analysis. Mean
fluorescence intensity was measured to be 656 for cells transduced
with SEQ ID NO: 27 (SSX-2 TCR), 910 for cells transduced with SEQ
ID NO: 29 (codon-optimized SSX-2 TCR), and 949 for cells transduced
with SEQ ID NO: 30 (codon-optimized SSX-2 TCR including mouse
constant region).
In another experiment, measurement of tetramer binding confirmed
that codon optimization and introduction of a mouse constant region
improved the expression of SSX-2 TCR in human PBLs.
In another experiment, FACS analysis also revealed that the
activation marker CD137 (4-1BB) was upregulated following
co-culture of human PBL transduced with SEQ ID NO: 27 (SSX-2 TCR),
SEQ ID NO: 29 (codon-optimized SSX-2 TCR), or SEQ ID NO: 30
(codon-optimized SSX-2 TCR including mouse constant region) with
COS-A2-SSX2 cells.
Another experiment evaluated the function of the SSX-2 TCRs by
measuring CD107a mobilization following coculture with COS-A2-SSX-2
cells. On Day 0, PBL were stimulated with OKT3. On Day 2, the PBL
were transduced as described in this example. On Day 15, the PBL
were co-cultured for 2 hours with COS-A2 cells or COS-A2-SSX-2
cells. On Day 16, CD107a mobilization was measured by FACS
analysis. The results showed that codon optimization and
introduction of a mouse constant region improved the function of
SSX-2 TCR as measured by CD107a mobilization following co-culture
with COS-A2-SSX-2 cells.
The function of the SSX-2 TCRs was also measured by IL-2 and
IFN-.gamma. production following co-culture with COS-A2-SSX-2 cells
or 938-A2 mel cells. PBL were stimulated with OKT3 and transduced
as described in this example. On Day 10, the PBL were co-cultured
with COS-A2 cells, COS-A2-SSX-2 cells, 938-A2 mel cells, or 938mel
cells. On Day 11, IL-2 and IFN-.gamma. production was measured by
FACS analysis. The results showed that codon optimization and
introduction of a mouse constant region improved the function of
SSX-2 TCR as measured by IL-2 and IFN-.gamma. production following
co-culture with COS-A2-SSX-2 cells and 938-A2 mel cells.
Example 7
This example demonstrates that PBLs engineered with the SSX-2 TCR,
codon-optimized SSX-2 TCR, or a codon-optimized human-mouse chimera
SSX-2 TCR show reactivity against tumor cell lines.
PBLs that were untransduced (UT) or transduced with a vector
comprising SEQ ID NO: 27 (SSX-2 TCR), SEQ ID NO: 29
(codon-optimized SSX-2 TCR), or SEQ ID NO: 30 (codon-optimized
SSX-2 TCR including mouse constant region) were co-cultured with
various tumor cell lines. Tables 5 and 6 show the resulting
interferon-.gamma. levels (pg/ml) measured with respect to PBL from
two different donors. These data show that the transduced T cells
recognized naturally processed and presented SSX-2 protein in
multiple tumor cell lines. PBLs that were not transduced with a
SSX-2 TCR (UT) showed very little or no reactivity.
TABLE-US-00006 TABLE 5 SSX2-TCR- SSX2-TCR-Co SSX2-TCR- WT (SEQ ID
Op (SEQ ID MCR (SEQ ID Cell line UT NO: 27) NO: 29) NO: 30) T cell
alone 445 165 164 327 K562 1950 1969 1714 2752 Lau 149 mel 925 285
193 270 T331A mel 47 30 30 30 Cos-A2 1280 2839 2338 2827 293-A2
1234 582 711 802 938 mel 1117 1239 890 1122 COS-A2-SSX2 615 52577
64142 56893 293-A2-SSX2 515 29804 37522 37258 K562-A2- 1830 12542
21325 17437 Erythroleukemia Skmel 37 mel 96 6635 8869 10401 1300
mel 176 2556 2596 2715 624 mel 453 27344 37547 46999 938-A2 mel 626
37032 46304 51092 U251 Glioma 372 16653 19223 19027 SKOV3 Ovarian
877 2414 2527 2221
TABLE-US-00007 TABLE 6 SSX2- SSX2-TCR-Co SSX2-TCR- Cell line UT
TCR-WT Op MCR T cell alone 180 322 290 554 K562 1734 1807 2784 3328
Lau 149 mel 124 125 120 142 T331A mel 115 58 30 38 Cos-A2 252 460
601 553 293-A2 994 1520 1067 1005 938 mel 915 1451 768 932
COS-A2-SSX2 65 85892 138324 164314 293-A2-SSX2 1027 52481 49112
47273 K562-A2- 1945 12825 13610 13555 Erythroleukemia Skmel 37 232
8941 11445 10630 1300 mel 258 3162 3052 3460 624 mel 2340 60174
47059 57693 938-A2 mel 2175 46094 51173 40047 U251 Glioma 656 22888
21418 20027 SKOV3 Ovarian 652 10953 22509 9857
Example 8
This example demonstrates that PBLs engineered with the SSX-2 TCR,
codon-optimized SSX-2 TCR, or a codon-optimized human-mouse chimera
SSX-2 TCR proliferate upon co-culture with SSX2+/HLA-A2+ target
cells.
PBLs from Donor 1 or Donor 2 that were untransduced (UT) or
transduced with a vector comprising SEQ ID NO: 27 (SSX-2 TCR), SEQ
ID NO: 29 (codon-optimized SSX-2 TCR), or SEQ ID NO: 30
(codon-optimized SSX-2 TCR including mouse constant region) were
co-cultured with COS-A2-SSX-2 cells. Proliferation in terms of
[.sup.3H]-thymidine incorporation (CPM) was measured and is shown
in FIG. 6A (Donor 1) and 6B (Donor 2). These data show that PBLs
transduced with SSX-2 TCR, codon-optimized SSX-2 TCR, or
codon-optimized SSX-2 TCR including mouse constant region
proliferate in response to co-culture with COS-A2-SSX-2 cells.
In another experiment, PBLs transduced as described in this example
were co-cultured with 1300 mel cells, 624 mel cells, 888 mel cells,
SK mel 37 cells, or COS-A2-SSX-2 cells. Proliferation in terms of
[.sup.3H]-thymidine incorporation counts per minute (CPM) was
measured and is shown in FIGS. 9A-9E. These data show that PBLs
transduced with SSX-2 TCR, codon-optimized SSX-2 TCR, or
codon-optimized SSX-2 TCR including mouse constant region
proliferate in response to co-culture with SSX2+/HLA-A2+ target
cells.
Example 9
This example demonstrates that PBLs engineered with the SSX-2 TCR,
codon-optimized SSX-2 TCR, or a codon-optimized human-mouse chimera
SSX-2 TCR show specific lytic activity against
SSX-2.sup.+/HLA-A2.sup.+ target cells.
PBLs that were untransduced (UT) or transduced with a vector
comprising SEQ ID NO: 27 (SSX-2 TCR), SEQ ID NO: 29
(codon-optimized SSX-2 TCR), or SEQ ID NO: 30 (codon-optimized
SSX-2 TCR including mouse constant region) were co-cultured with
target cells 938 mel (HLA-A2-/SSX-2+), COS-A2, 938-A2 mel,
COS-A2-SSX-2, 624 mel, 1300 mel, SK mel 37, or 888 mel at the
effector to target ratios set forth in FIGS. 7A-D and 8A-D. Percent
lysis of the target cells was measured and is shown in FIGS. 7A-D
and 8A-D. Untransduced cells showed little to no reactivity. These
data show that PBLs engineered with the SSX-2 TCR, codon-optimized
SSX-2 TCR, or a codon-optimized human-mouse chimera SSX-2 TCR show
specific lytic activity against SSX-2.sup.+/HLA-A2.sup.+ target
cells.
Example 10
This example demonstrates that PBLs engineered with the SSX-2 TCR,
codon-optimized SSX-2 TCR, or a codon-optimized human-mouse chimera
SSX-2 TCR secrete cytokine when co-cultured with peptide-pulsed T2
cells.
PBLs that were untransduced (UT) or transduced with a vector
comprising SEQ ID NO: 27 (SSX-2 TCR), SEQ ID NO: 29
(codon-optimized SSX-2 TCR), or SEQ ID NO: 30 (codon-optimized
SSX-2 TCR including mouse constant region) were co-cultured with T2
cells that were pulsed with an SSX-2 were pulsed with varying
concentrations of the SSX-2: 41-49 (KASEKIFYV) (SEQ ID NO: 1)
peptide. FIG. 10 shows the resulting interferon-.gamma. levels
(pg/ml) measured. These data show that SSX-2 TCR-transduced PBLs
recognize SSX-2: 41-49 peptide.
Example 11
This example demonstrates that the demethylating agent,
5-aza-2'-deoxycytidine (DAC), enhances the recognition of mel1300
cells by SSX2-TCR engineered PBL.
SSX-2 TCR-transduced PBLs from three donors were co-cultured with
mel1300 cells without DAC or with 0.1 .mu.M or 1.0 .mu.WI DAC. FIG.
12 shows the resulting interferon-.gamma. levels (pg/ml) measured.
These data show that DAC enhances the recognition of mel1300 cells
by SSX2-TCR engineered PBL.
All references, including publications, patent applications, and
patents, cited herein are hereby incorporated by reference to the
same extent as if each reference were individually and specifically
indicated to be incorporated by reference and were set forth in its
entirety herein.
The use of the terms "a" and "an" and "the" and similar referents
in the context of describing the invention (especially in the
context of the following claims) are to be construed to cover both
the singular and the plural, unless otherwise indicated herein or
clearly contradicted by context. The terms "comprising," "having,"
"including," and "containing" are to be construed as open-ended
terms (i.e., meaning "including, but not limited to,") unless
otherwise noted. Recitation of ranges of values herein are merely
intended to serve as a shorthand method of referring individually
to each separate value falling within the range, unless otherwise
indicated herein, and each separate value is incorporated into the
specification as if it were individually recited herein. All
methods described herein can be performed in any suitable order
unless otherwise indicated herein or otherwise clearly contradicted
by context. The use of any and all examples, or exemplary language
(e.g., "such as") provided herein, is intended merely to better
illuminate the invention and does not pose a limitation on the
scope of the invention unless otherwise claimed. No language in the
specification should be construed as indicating any non-claimed
element as essential to the practice of the invention.
Preferred embodiments of this invention are described herein,
including the best mode known to the inventors for carrying out the
invention. Variations of those preferred embodiments may become
apparent to those of ordinary skill in the art upon reading the
foregoing description. The inventors expect skilled artisans to
employ such variations as appropriate, and the inventors intend for
the invention to be practiced otherwise than as specifically
described herein. Accordingly, this invention includes all
modifications and equivalents of the subject matter recited in the
claims appended hereto as permitted by applicable law. Moreover,
any combination of the above-described elements in all possible
variations thereof is encompassed by the invention unless otherwise
indicated herein or otherwise clearly contradicted by context.
SEQUENCE LISTINGS
1
381223PRTHomo sapiens 1Met Asn Gly Asp Asp Ala Phe Ala Arg Arg Pro
Thr Val Gly Ala Gln1 5 10 15Ile Pro Glu Lys Ile Gln Lys Ala Phe Asp
Asp Ile Ala Lys Tyr Phe 20 25 30Ser Lys Glu Glu Trp Glu Lys Met Lys
Ala Ser Glu Lys Ile Phe Tyr 35 40 45Val Tyr Met Lys Arg Lys Tyr Glu
Ala Met Thr Lys Leu Gly Phe Lys 50 55 60Ala Thr Leu Pro Pro Phe Met
Cys Asn Lys Arg Ala Glu Asp Phe Gln65 70 75 80Gly Asn Asp Leu Asp
Asn Asp Pro Asn Arg Gly Asn Gln Val Glu Arg 85 90 95Pro Gln Met Thr
Phe Gly Arg Leu Gln Gly Ile Ser Pro Lys Ile Met 100 105 110Pro Lys
Lys Pro Ala Glu Glu Gly Asn Asp Ser Glu Glu Val Pro Glu 115 120
125Ala Ser Gly Pro Gln Asn Asp Gly Lys Glu Leu Cys Pro Pro Gly Lys
130 135 140Pro Thr Thr Ser Glu Lys Ile His Glu Arg Ser Gly Asn Arg
Glu Ala145 150 155 160Gln Glu Lys Glu Glu Arg Arg Gly Thr Ala His
Arg Trp Ser Ser Gln 165 170 175Asn Thr His Asn Ile Gly Arg Phe Ser
Leu Ser Thr Ser Met Gly Ala 180 185 190Val His Gly Thr Pro Lys Thr
Ile Thr His Asn Arg Asp Pro Lys Gly 195 200 205Gly Asn Met Pro Gly
Pro Thr Asp Cys Val Arg Glu Asn Ser Trp 210 215 22029PRTHomo
sapiens 2Lys Ala Ser Glu Lys Ile Phe Tyr Val1 53188PRTHomo sapiens
3Met Asn Gly Asp Asp Thr Phe Ala Arg Arg Pro Thr Val Gly Ala Gln1 5
10 15Ile Pro Glu Lys Ile Gln Lys Ala Phe Asp Asp Ile Ala Lys Tyr
Phe 20 25 30Ser Lys Glu Glu Trp Glu Lys Met Lys Val Ser Glu Lys Ile
Val Tyr 35 40 45Val Tyr Met Lys Arg Lys Tyr Glu Ala Met Thr Lys Leu
Gly Phe Lys 50 55 60Ala Ile Leu Pro Ser Phe Met Arg Asn Lys Arg Val
Thr Asp Phe Gln65 70 75 80Gly Asn Asp Phe Asp Asn Asp Pro Asn Arg
Gly Asn Gln Val Gln Arg 85 90 95Pro Gln Met Thr Phe Gly Arg Leu Gln
Gly Ile Phe Pro Lys Ile Met 100 105 110Pro Lys Lys Pro Ala Glu Glu
Gly Asn Val Ser Lys Glu Val Pro Glu 115 120 125Ala Ser Gly Pro Gln
Asn Asp Gly Lys Gln Leu Cys Pro Pro Gly Lys 130 135 140Pro Thr Thr
Ser Glu Lys Ile Asn Met Ile Ser Gly Pro Lys Arg Gly145 150 155
160Glu His Ala Trp Thr His Arg Leu Arg Glu Arg Lys Gln Leu Val Ile
165 170 175Tyr Glu Glu Ile Ser Asp Pro Glu Glu Asp Asp Glu 180
1854188PRTHomo sapiens 4Met Asn Gly Asp Asp Ala Phe Ala Arg Arg Pro
Arg Asp Asp Ala Gln1 5 10 15Ile Ser Glu Lys Leu Arg Lys Ala Phe Asp
Asp Ile Ala Lys Tyr Phe 20 25 30Ser Lys Lys Glu Trp Glu Lys Met Lys
Ser Ser Glu Lys Ile Val Tyr 35 40 45Val Tyr Met Lys Leu Asn Tyr Glu
Val Met Thr Lys Leu Gly Phe Lys 50 55 60Val Thr Leu Pro Pro Phe Met
Arg Ser Lys Arg Ala Ala Asp Phe His65 70 75 80Gly Asn Asp Phe Gly
Asn Asp Arg Asn His Arg Asn Gln Val Glu Arg 85 90 95Pro Gln Met Thr
Phe Gly Ser Leu Gln Arg Ile Phe Pro Lys Ile Met 100 105 110Pro Lys
Lys Pro Ala Glu Glu Glu Asn Gly Leu Lys Glu Val Pro Glu 115 120
125Ala Ser Gly Pro Gln Asn Asp Gly Lys Gln Leu Cys Pro Pro Gly Asn
130 135 140Pro Ser Thr Leu Glu Lys Ile Asn Lys Thr Ser Gly Pro Lys
Arg Gly145 150 155 160Lys His Ala Trp Thr His Arg Leu Arg Glu Arg
Lys Gln Leu Val Val 165 170 175Tyr Glu Glu Ile Ser Asp Pro Glu Glu
Asp Asp Glu 180 1855229PRTHomo sapiens 5Met Asn Gly Asp Asp Ala Phe
Val Arg Arg Pro Arg Val Gly Ser Gln1 5 10 15Ile Pro Gln Lys Met Gln
Lys His Pro Trp Arg Gln Val Cys Asp Arg 20 25 30Gly Ile His Leu Val
Asn Leu Ser Pro Phe Trp Lys Val Gly Arg Glu 35 40 45Pro Ala Ser Ser
Ile Lys Ala Leu Leu Cys Gly Arg Gly Glu Ala Arg 50 55 60Ala Phe Asp
Asp Ile Ala Lys Tyr Phe Ser Glu Lys Glu Trp Glu Lys65 70 75 80Met
Lys Ala Ser Glu Lys Ile Ile Tyr Val Tyr Met Lys Arg Lys Tyr 85 90
95Glu Ala Met Thr Lys Leu Gly Phe Lys Ala Thr Leu Pro Pro Phe Met
100 105 110Arg Asn Lys Arg Val Ala Asp Phe Gln Gly Asn Asp Phe Asp
Asn Asp 115 120 125Pro Asn Arg Gly Asn Gln Val Glu His Pro Gln Met
Thr Phe Gly Arg 130 135 140Leu Gln Gly Ile Phe Pro Lys Ile Thr Pro
Glu Lys Pro Ala Glu Glu145 150 155 160Gly Asn Asp Ser Lys Gly Val
Pro Glu Ala Ser Gly Pro Gln Asn Asn 165 170 175Gly Lys Gln Leu Arg
Pro Ser Gly Lys Leu Asn Thr Ser Glu Lys Val 180 185 190Asn Lys Thr
Ser Gly Pro Lys Arg Gly Lys His Ala Trp Thr His Arg 195 200 205Val
Arg Glu Arg Lys Gln Leu Val Ile Tyr Glu Glu Ile Ser Asp Pro 210 215
220Gln Glu Asp Asp Glu2256188PRTHomo sapiens 6Met Asn Gly Asp Asp
Ala Phe Ala Arg Arg Pro Arg Ala Gly Ser Gln1 5 10 15Ile Pro Glu Lys
Ile Gln Lys Ala Phe Asp Asp Ile Ala Lys Tyr Phe 20 25 30Ser Lys Lys
Glu Trp Glu Lys Met Lys Ser Ser Glu Lys Ile Ile Tyr 35 40 45Val Tyr
Met Lys Arg Lys Tyr Glu Ala Met Thr Lys Leu Gly Phe Lys 50 55 60Ala
Thr Leu Pro Pro Phe Met Cys Asn Thr Gly Ala Thr Asp Leu Gln65 70 75
80Gly Asn Asp Phe Asp Asn Asp Arg Asn His Arg Asn Gln Val Glu Arg
85 90 95Ser Gln Met Thr Phe Gly Arg Leu Gln Gly Ile Phe Pro Lys Ile
Met 100 105 110Pro Lys Lys Pro Ala Glu Val Gly Asn Asp Ser Lys Glu
Val Pro Glu 115 120 125Ala Ser Gly Leu Gln Asn Asp Gly Lys Gln Leu
Cys Pro Pro Gly Lys 130 135 140Pro Thr Thr Ser Glu Lys Ile Asn Lys
Ala Ser Gly Pro Lys Arg Gly145 150 155 160Lys His Ala Trp Thr His
Arg Leu Arg Glu Arg Lys Gln Leu Val Ile 165 170 175Tyr Glu Glu Ile
Ser Asp Pro Glu Glu Asp Asp Glu 180 1857151PRTHomo sapiens 7Met Asn
Gly Asp Asp Ala Phe Ala Arg Arg Pro Arg Val Asp Ala Gln1 5 10 15Ile
Pro Glu Lys Ile Gln Lys Ala Phe Asp Asp Ile Ala Lys Tyr Phe 20 25
30Ser Lys Glu Glu Trp Glu Lys Met Lys Ala Ser Glu Lys Ile Leu Tyr
35 40 45Val Tyr Met Lys Arg Lys Tyr Glu Ala Met Thr Lys Leu Gly Phe
Lys 50 55 60Ala Thr Leu Pro Pro Phe Met Cys Asn Lys Arg Thr Ala Asp
Phe Gln65 70 75 80Gly Asn Asp Phe Asp Asn Asp Tyr Asn His Gly His
Gln Gly Ser Thr 85 90 95Val His Ala Ser Ser Ser Phe Leu His Val Pro
Gln Met Thr Ile Ser 100 105 110Ser Val Ser Leu Pro Thr Tyr Ser Gln
Met Asp His Pro Ser Pro Arg 115 120 125Thr Arg Lys Leu Phe Arg Glu
Arg Arg Pro Asn Cys Pro Thr Thr Cys 130 135 140Cys Arg Ile Leu Leu
Gln Asp145 15089PRTHomo sapiens 8Lys Val Ser Glu Lys Ile Val Tyr
Val1 599PRTHomo sapiens 9Lys Ser Ser Glu Lys Ile Val Tyr Val1
5109PRTHomo sapiens 10Lys Ala Ser Glu Lys Ile Ile Tyr Val1
5119PRTHomo sapiens 11Lys Ser Ser Glu Lys Ile Ile Tyr Val1
5129PRTHomo sapiens 12Lys Ala Ser Glu Lys Ile Leu Tyr Val1
5137PRTHomo sapiens 13Thr Ser Asp Pro Ser Tyr Gly1 5144PRTHomo
sapiens 14Gln Gly Ser Tyr11514PRTHomo sapiens 15Cys Ala Met Thr Ser
Gly Phe Gly Asn Glu Lys Leu Thr Phe1 5 10165PRTHomo sapiens 16Leu
Asn His Asn Val1 5176PRTHomo sapiens 17Tyr Tyr Asp Lys Asp Phe1
51814PRTHomo sapiens 18Cys Ala Thr Ser Arg Gly Gln Gly Gly Gln Pro
Gln His Phe1 5 1019115PRTHomo sapiens 19Ala Gln Lys Ile Thr Gln Thr
Gln Pro Gly Met Phe Val Gln Glu Lys1 5 10 15Glu Ala Val Thr Leu Asp
Cys Thr Tyr Asp Thr Ser Asp Pro Ser Tyr 20 25 30Gly Leu Phe Trp Tyr
Lys Gln Pro Ser Ser Gly Glu Met Ile Phe Leu 35 40 45Ile Tyr Gln Gly
Ser Tyr Asp Gln Gln Asn Ala Thr Glu Gly Arg Tyr 50 55 60Ser Leu Asn
Phe Gln Lys Ala Arg Lys Ser Ala Asn Leu Val Ile Ser65 70 75 80Ala
Ser Gln Leu Gly Asp Ser Ala Met Tyr Phe Cys Ala Met Thr Ser 85 90
95Gly Phe Gly Asn Glu Lys Leu Thr Phe Gly Thr Gly Thr Arg Leu Thr
100 105 110Ile Ile Pro 11520114PRTHomo sapiens 20Asp Ala Met Val
Ile Gln Asn Pro Arg Tyr Gln Val Thr Gln Phe Gly1 5 10 15Lys Pro Val
Thr Leu Ser Cys Ser Gln Thr Leu Asn His Asn Val Met 20 25 30Tyr Trp
Tyr Gln Gln Lys Ser Ser Gln Ala Pro Lys Leu Leu Phe His 35 40 45Tyr
Tyr Asp Lys Asp Phe Asn Asn Glu Ala Asp Thr Pro Asp Asn Phe 50 55
60Gln Ser Arg Arg Pro Asn Thr Ser Phe Cys Phe Leu Asp Ile Arg Ser65
70 75 80Pro Gly Leu Gly Asp Ala Ala Met Tyr Leu Cys Ala Thr Ser Arg
Gly 85 90 95Gln Gly Gly Gln Pro Gln His Phe Gly Asp Gly Thr Arg Leu
Ser Ile 100 105 110Leu Glu21137PRTMus musculus 21Asp Ile Gln Asn
Pro Glu Pro Ala Val Tyr Gln Leu Lys Asp Pro Arg1 5 10 15Ser Gln Asp
Ser Thr Leu Cys Leu Phe Thr Asp Phe Asp Ser Gln Ile 20 25 30Asn Val
Pro Lys Thr Met Glu Ser Gly Thr Phe Ile Thr Asp Lys Thr 35 40 45Val
Leu Asp Met Lys Ala Met Asp Ser Lys Ser Asn Gly Ala Ile Ala 50 55
60Trp Ser Asn Gln Thr Ser Phe Thr Cys Gln Asp Ile Phe Lys Glu Thr65
70 75 80Asn Ala Thr Tyr Pro Ser Ser Asp Val Pro Cys Asp Ala Thr Leu
Thr 85 90 95Glu Lys Ser Phe Glu Thr Asp Met Asn Leu Asn Phe Gln Asn
Leu Ser 100 105 110Val Met Gly Leu Arg Ile Leu Leu Leu Lys Val Ala
Gly Phe Asn Leu 115 120 125Leu Met Thr Leu Arg Leu Trp Ser Ser 130
13522170PRTMus musculus 22Asp Leu Arg Asn Val Thr Pro Pro Lys Val
Ser Leu Phe Glu Pro Ser1 5 10 15Lys Ala Glu Ile Ala Asn Lys Gln Lys
Ala Thr Leu Val Cys Leu Ala 20 25 30Arg Gly Phe Phe Pro Asp His Val
Glu Leu Ser Trp Trp Val Asn Gly 35 40 45Lys Glu Val His Ser Gly Val
Ser Thr Asp Pro Gln Ala Tyr Lys Glu 50 55 60Ser Asn Tyr Ser Tyr Cys
Leu Ser Ser Arg Leu Arg Val Ser Ala Thr65 70 75 80Phe Trp His Asn
Pro Arg Asn His Phe Arg Cys Gln Val Gln Phe His 85 90 95Gly Leu Ser
Glu Glu Asp Lys Trp Pro Glu Gly Ser Pro Lys Pro Val 100 105 110Thr
Gln Asn Ile Ser Ala Glu Ala Trp Gly Arg Ala Cys Gly Ile Thr 115 120
125Ser Ser Tyr Gln Gln Gly Val Leu Ser Ala Thr Ile Leu Tyr Glu Ile
130 135 140Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu Val Ser Thr
Leu Val145 150 155 160Val Met Ala Met Val Lys Arg Lys Asn Ser 165
17023276PRTHomo sapiens 23Met Ser Leu Ser Ser Leu Leu Lys Val Val
Thr Ala Ser Leu Trp Leu1 5 10 15Gly Pro Gly Ile Ala Gln Lys Ile Thr
Gln Thr Gln Pro Gly Met Phe 20 25 30Val Gln Glu Lys Glu Ala Val Thr
Leu Asp Cys Thr Tyr Asp Thr Ser 35 40 45Asp Pro Ser Tyr Gly Leu Phe
Trp Tyr Lys Gln Pro Ser Ser Gly Glu 50 55 60Met Ile Phe Leu Ile Tyr
Gln Gly Ser Tyr Asp Gln Gln Asn Ala Thr65 70 75 80Glu Gly Arg Tyr
Ser Leu Asn Phe Gln Lys Ala Arg Lys Ser Ala Asn 85 90 95Leu Val Ile
Ser Ala Ser Gln Leu Gly Asp Ser Ala Met Tyr Phe Cys 100 105 110Ala
Met Thr Ser Gly Phe Gly Asn Glu Lys Leu Thr Phe Gly Thr Gly 115 120
125Thr Arg Leu Thr Ile Ile Pro Asn Ile Gln Asn Pro Asp Pro Ala Val
130 135 140Tyr Gln Leu Arg Asp Ser Lys Ser Ser Asp Lys Ser Val Cys
Leu Phe145 150 155 160Thr Asp Phe Asp Ser Gln Thr Asn Val Ser Gln
Ser Lys Asp Ser Asp 165 170 175Val Tyr Ile Thr Asp Lys Thr Val Leu
Asp Met Arg Ser Met Asp Phe 180 185 190Lys Ser Asn Ser Ala Val Ala
Trp Ser Asn Lys Ser Asp Phe Ala Cys 195 200 205Ala Asn Ala Phe Asn
Asn Ser Ile Ile Pro Glu Asp Thr Phe Phe Pro 210 215 220Ser Pro Glu
Ser Ser Cys Asp Val Lys Leu Val Glu Lys Ser Phe Glu225 230 235
240Thr Asp Thr Asn Leu Asn Phe Gln Asn Leu Ser Val Ile Gly Phe Arg
245 250 255Ile Leu Leu Leu Lys Val Ala Gly Phe Asn Leu Leu Met Thr
Leu Arg 260 265 270Leu Trp Ser Ser 27524309PRTHomo sapiens 24Met
Gly Pro Gly Leu Leu His Trp Met Ala Leu Cys Leu Leu Gly Thr1 5 10
15Gly His Gly Asp Ala Met Val Ile Gln Asn Pro Arg Tyr Gln Val Thr
20 25 30Gln Phe Gly Lys Pro Val Thr Leu Ser Cys Ser Gln Thr Leu Asn
His 35 40 45Asn Val Met Tyr Trp Tyr Gln Gln Lys Ser Ser Gln Ala Pro
Lys Leu 50 55 60Leu Phe His Tyr Tyr Asp Lys Asp Phe Asn Asn Glu Ala
Asp Thr Pro65 70 75 80Asp Asn Phe Gln Ser Arg Arg Pro Asn Thr Ser
Phe Cys Phe Leu Asp 85 90 95Ile Arg Ser Pro Gly Leu Gly Asp Ala Ala
Met Tyr Leu Cys Ala Thr 100 105 110Ser Arg Gly Gln Gly Gly Gln Pro
Gln His Phe Gly Asp Gly Thr Arg 115 120 125Leu Ser Ile Leu Glu Asp
Leu Asn Lys Val Phe Pro Pro Glu Val Ala 130 135 140Val Phe Glu Pro
Ser Glu Ala Glu Ile Ser His Thr Gln Lys Ala Thr145 150 155 160Leu
Val Cys Leu Ala Thr Gly Phe Phe Pro Asp His Val Glu Leu Ser 165 170
175Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
180 185 190Gln Pro Leu Lys Glu Gln Pro Ala Leu Asn Asp Ser Arg Tyr
Cys Leu 195 200 205Ser Ser Arg Leu Arg Val Ser Ala Thr Phe Trp Gln
Asn Pro Arg Asn 210 215 220His Phe Arg Cys Gln Val Gln Phe Tyr Gly
Leu Ser Glu Asn Asp Glu225 230 235 240Trp Thr Gln Asp Arg Ala Lys
Pro Val Thr Gln Ile Val Ser Ala Glu 245 250 255Ala Trp Gly Arg Ala
Asp Cys Gly Phe Thr Ser Val Ser Tyr Gln Gln 260 265 270Gly Val Leu
Ser Ala Thr Ile Leu Tyr Glu Ile Leu Leu Gly Lys Ala 275 280 285Thr
Leu Tyr Ala Val Leu Val Ser Ala Leu Val Leu Met Ala Met Val 290 295
300Lys Arg Lys Asp Phe30525273PRTArtificial SequenceSynthetic
Polypeptide 25Met Ser Leu Ser Ser Leu Leu Lys Val Val Thr Ala Ser
Leu Trp Leu1 5 10 15Gly Pro Gly Ile Ala Gln Lys Ile Thr Gln Thr Gln
Pro Gly Met Phe 20 25 30Val Gln Glu Lys Glu Ala Val Thr Leu Asp Cys
Thr Tyr Asp Thr Ser
35 40 45Asp Pro Ser Tyr Gly Leu Phe Trp Tyr Lys Gln Pro Ser Ser Gly
Glu 50 55 60Met Ile Phe Leu Ile Tyr Gln Gly Ser Tyr Asp Gln Gln Asn
Ala Thr65 70 75 80Glu Gly Arg Tyr Ser Leu Asn Phe Gln Lys Ala Arg
Lys Ser Ala Asn 85 90 95Leu Val Ile Ser Ala Ser Gln Leu Gly Asp Ser
Ala Met Tyr Phe Cys 100 105 110Ala Met Thr Ser Gly Phe Gly Asn Glu
Lys Leu Thr Phe Gly Thr Gly 115 120 125Thr Arg Leu Thr Ile Ile Pro
Asn Asp Ile Gln Asn Pro Glu Pro Ala 130 135 140Val Tyr Gln Leu Lys
Asp Pro Arg Ser Gln Asp Ser Thr Leu Cys Leu145 150 155 160Phe Thr
Asp Phe Asp Ser Gln Ile Asn Val Pro Lys Thr Met Glu Ser 165 170
175Gly Thr Phe Ile Thr Asp Lys Thr Val Leu Asp Met Lys Ala Met Asp
180 185 190Ser Lys Ser Asn Gly Ala Ile Ala Trp Ser Asn Gln Thr Ser
Phe Thr 195 200 205Cys Gln Asp Ile Phe Lys Glu Thr Asn Ala Thr Tyr
Pro Ser Ser Asp 210 215 220Val Pro Cys Asp Ala Thr Leu Thr Glu Lys
Ser Phe Glu Thr Asp Met225 230 235 240Asn Leu Asn Phe Gln Asn Leu
Ser Val Met Gly Leu Arg Ile Leu Leu 245 250 255Leu Lys Val Ala Gly
Phe Asn Leu Leu Met Thr Leu Arg Leu Trp Ser 260 265
270Ser26303PRTArtificial SequenceSynthetic Polypeptide 26Met Gly
Pro Gly Leu Leu His Trp Met Ala Leu Cys Leu Leu Gly Thr1 5 10 15Gly
His Gly Asp Ala Met Val Ile Gln Asn Pro Arg Tyr Gln Val Thr 20 25
30Gln Phe Gly Lys Pro Val Thr Leu Ser Cys Ser Gln Thr Leu Asn His
35 40 45Asn Val Met Tyr Trp Tyr Gln Gln Lys Ser Ser Gln Ala Pro Lys
Leu 50 55 60Leu Phe His Tyr Tyr Asp Lys Asp Phe Asn Asn Glu Ala Asp
Thr Pro65 70 75 80Asp Asn Phe Gln Ser Arg Arg Pro Asn Thr Ser Phe
Cys Phe Leu Asp 85 90 95Ile Arg Ser Pro Gly Leu Gly Asp Ala Ala Met
Tyr Leu Cys Ala Thr 100 105 110Ser Arg Gly Gln Gly Gly Gln Pro Gln
His Phe Gly Asp Gly Thr Arg 115 120 125Leu Ser Ile Leu Glu Asp Leu
Arg Asn Val Thr Pro Pro Lys Val Ser 130 135 140Leu Phe Glu Pro Ser
Lys Ala Glu Ile Ala Asn Lys Gln Lys Ala Thr145 150 155 160Leu Val
Cys Leu Ala Arg Gly Phe Phe Pro Asp His Val Glu Leu Ser 165 170
175Trp Trp Val Asn Gly Lys Glu Val His Ser Gly Val Ser Thr Asp Pro
180 185 190Gln Ala Tyr Lys Glu Ser Asn Tyr Ser Tyr Cys Leu Ser Ser
Arg Leu 195 200 205Arg Val Ser Ala Thr Phe Trp His Asn Pro Arg Asn
His Phe Arg Cys 210 215 220Gln Val Gln Phe His Gly Leu Ser Glu Glu
Asp Lys Trp Pro Glu Gly225 230 235 240Ser Pro Lys Pro Val Thr Gln
Asn Ile Ser Ala Glu Ala Trp Gly Arg 245 250 255Ala Cys Gly Ile Thr
Ser Ser Tyr Gln Gln Gly Val Leu Ser Ala Thr 260 265 270Ile Leu Tyr
Glu Ile Leu Leu Gly Lys Ala Thr Leu Tyr Ala Val Leu 275 280 285Val
Ser Thr Leu Val Val Met Ala Met Val Lys Arg Lys Asn Ser 290 295
300271842DNAArtificial SequenceSynthetic Polynucleotide
27atgtcacttt ctagcctgct gaaggtggtc acagcttcac tgtggctagg acctggcatt
60gcccagaaga taactcaaac ccaaccagga atgttcgtgc aggaaaagga ggctgtgact
120ctggactgca catatgacac cagtgatcca agttatggtc tattctggta
caagcagccc 180agcagtgggg aaatgatttt tcttatttat caggggtctt
atgaccagca aaatgcaaca 240gaaggtcgct actcattgaa tttccagaag
gcaagaaaat ccgccaacct tgtcatctcc 300gcttcacaac tgggggactc
agcaatgtac ttctgtgcaa tgaccagcgg gtttggaaat 360gagaaattaa
cctttgggac tggaacaaga ctcaccatca tacccaatat ccagaaccct
420gaccctgccg tgtaccagct gagagactct aaatccagtg acaagtctgt
ctgcctattc 480accgattttg attctcaaac aaatgtgtca caaagtaagg
attctgatgt gtatatcaca 540gacaaaactg tgctagacat gaggtctatg
gacttcaaga gcaacagtgc tgtggcctgg 600agcaacaaat ctgactttgc
atgtgcaaac gccttcaaca acagcattat tccagaagac 660accttcttcc
ccagcccaga aagttcctgt gatgtcaagc tggtcgagaa aagctttgaa
720acagatacga acctaaactt tcaaaacctg tcagtgattg ggttccgaat
cctcctcctg 780aaagtggccg ggtttaatct gctcatgacg ctgcggctgt
ggtccagccg ggccaagcgg 840tccggatccg gagccaccaa cttcagcctg
ctgaagcagg cgggcgacgt ggaggagaac 900cccggcccca tgggtcctgg
gcttctccac tggatggccc tttgtctcct tggaacaggt 960catggggatg
ccatggtcat ccagaaccca agataccagg ttacccagtt tggaaagcca
1020gtgaccctga gttgttctca gactttgaac cataacgtca tgtactggta
ccagcagaag 1080tcaagtcagg ccccaaagct gctgttccac tactatgaca
aagattttaa caatgaagca 1140gacacccctg ataacttcca atccaggagg
ccgaacactt ctttctgctt tcttgacatc 1200cgctcaccag gcctggggga
cgcagccatg tacctgtgtg ccaccagcag aggacagggt 1260gggcagcccc
agcattttgg tgatgggact cgactctcca tcctagagga cctgaacaag
1320gtgttcccac ccgaggtcgc tgtgtttgag ccatcagaag cagagatctc
ccacacccaa 1380aaggccacac tggtgtgcct ggccacaggc ttcttccctg
accacgtgga gctgagctgg 1440tgggtgaatg ggaaggaggt gcacagtggg
gtcagcacgg acccgcagcc cctcaaggag 1500cagcccgccc tcaatgactc
cagatactgc ctgagcagcc gcctgagggt ctcggccacc 1560ttctggcaga
acccccgcaa ccacttccgc tgtcaagtcc agttctacgg gctctcggag
1620aatgacgagt ggacccagga tagggccaaa cccgtcaccc agatcgtcag
cgccgaggcc 1680tggggtagag cagactgtgg ctttacctcg gtgtcctacc
agcaaggggt cctgtctgcc 1740accatcctct atgagatcct gctagggaag
gccaccctgt atgctgtgct ggtcagcgcc 1800cttgtgttga tggccatggt
caagagaaag gatttctgat aa 1842281815DNAArtificial SequenceSynthetic
Polynucleotide 28atgtcacttt ctagcctgct gaaggtggtc acagcttcac
tgtggctagg acctggcatt 60gcccagaaga taactcaaac ccaaccagga atgttcgtgc
aggaaaagga ggctgtgact 120ctggactgca catatgacac cagtgatcca
agttatggtc tattctggta caagcagccc 180agcagtgggg aaatgatttt
tcttatttat caggggtctt atgaccagca aaatgcaaca 240gaaggtcgct
actcattgaa tttccagaag gcaagaaaat ccgccaacct tgtcatctcc
300gcttcacaac tgggggactc agcaatgtac ttctgtgcaa tgaccagcgg
gtttggaaat 360gagaaattaa cctttgggac tggaacaaga ctcaccatca
tacccaatga catccagaac 420ccagaacctg ctgtgtacca gttaaaagat
cctcggtctc aggacagcac cctctgcctg 480ttcaccgact ttgactccca
aatcaatgtg ccgaaaacca tggaatctgg aacgttcatc 540actgacaaaa
ctgtgctgga catgaaagct atggattcca agagcaatgg ggccattgcc
600tggagcaacc agacaagctt cacctgccaa gatatcttca aagagaccaa
cgccacctac 660cccagttcag acgttccctg tgatgccacg ttgactgaga
aaagctttga aacagatatg 720aacctaaact ttcaaaacct gtcagttatg
ggactccgaa tcctcctgct gaaagtagcc 780ggatttaacc tgctcatgac
gctgaggctg tggtccagtc gggccaagcg gtccggatcc 840ggagccacca
acttcagcct gctgaagcag gcgggcgacg tggaggagaa ccccggcccc
900atgggtcctg ggcttctcca ctggatggcc ctttgtctcc ttggaacagg
tcatggggat 960gccatggtca tccagaaccc aagataccag gttacccagt
ttggaaagcc agtgaccctg 1020agttgttctc agactttgaa ccataacgtc
atgtactggt accagcagaa gtcaagtcag 1080gccccaaagc tgctgttcca
ctactatgac aaagatttta acaatgaagc agacacccct 1140gataacttcc
aatccaggag gccgaacact tctttctgct ttcttgacat ccgctcacca
1200ggcctggggg acgcagccat gtacctgtgt gccaccagca gaggacaggg
tgggcagccc 1260cagcattttg gtgatgggac tcgactctcc atcctagagg
atctgagaaa tgtgactcca 1320cccaaggtct ccttgtttga gccatcaaaa
gcagagattg caaacaaaca aaaggctacc 1380ctcgtgtgct tggccagggg
cttcttccct gaccacgtgg agctgagctg gtgggtgaat 1440ggcaaggagg
tccacagtgg ggtcagcacg gaccctcagg cctacaagga gagcaattat
1500agctactgcc tgagcagccg cctgagggtc tctgctacct tctggcacaa
tcctcgcaac 1560cacttccgct gccaagtgca gttccatggg ctttcagagg
aggacaagtg gccagagggc 1620tcacccaaac ctgtcacaca gaacatcagt
gcagaggcct ggggccgagc atgtgggatt 1680acctcatcct atcaacaagg
ggtcttgtct gccaccatcc tctatgagat cctgctaggg 1740aaagccaccc
tgtatgctgt gcttgtcagt acactggtgg tgatggctat ggtcaaaaga
1800aagaactcat gataa 1815291842DNAArtificial SequenceSynthetic
Polynucleotide 29atggcactga gcagcctgct gaaggtggtg acagccagcc
tgtggctggg ccctggaatc 60gcccagaaga tcacccagac ccagcccggc atgttcgtgc
aggaaaaaga agccgtgacc 120ctggactgca cctacgacac cagcgacccc
agctacggcc tgttctggta caagcagccc 180agcagcggcg agatgatctt
cctgatctac cagggcagct acgaccagca gaacgccacc 240gagggccggt
acagcctcaa cttccagaag gcccggaagt ccgccaacct ggtgatcagc
300gccagccagc tgggcgacag cgccatgtac ttttgcgcca tgaccagcgg
cttcggcaac 360gagaagctga ccttcggcac cggcacccgg ctgaccatca
tccccaacat ccagaacccc 420gatcctgctg tgtaccagct gagggacagc
aagagcagcg acaagagcgt gtgcctgttc 480accgacttcg acagccagac
caacgtgtct cagtctaagg atagtgatgt gtatatcacc 540gacaagaccg
tgctggacat gcggagcatg gacttcaaga gcaacagcgc cgtggcctgg
600tccaacaaga gcgacttcgc ctgcgccaac gccttcaaca acagcatcat
ccccgaggac 660acctttttcc ccagccccga gagcagctgc gacgtgaaac
tggtggagaa gagcttcgag 720acagacacca acctgaactt ccagaacctg
agcgtgatcg gcttcagaat cctgctgctg 780aaggtggccg gcttcaacct
gctgatgacc ctgcggctgt ggagcagccg ggccaagaga 840agcggcagcg
gcgccaccaa cttcagcctg ctgaagcagg ccggcgacgt ggaggaaaac
900cctggcccta tgggacctgg cctgctgcac tggatggccc tgtgtctgct
gggcacaggc 960cacggcgacg ctatggtgat ccagaatccc agataccagg
tgacacagtt cggcaagccc 1020gtgacactga gctgcagcca gaccctgaac
cacaacgtga tgtactggta tcagcagaag 1080tccagccagg cccccaagct
gctgttccac tactacgaca aggacttcaa caacgaggcc 1140gacacccccg
acaacttcca gagcagacgg cccaatacca gcttctgctt cctggacatc
1200agaagccctg gcctggggga cgccgccatg tacctgtgtg ccaccagcag
aggccagggc 1260ggacagcccc agcacttcgg cgacggcacc agactgagca
tcctcgagga cctgaacaag 1320gtgttccccc ccgaggtggc cgtgttcgag
cccagcgagg ccgagattag ccacacccag 1380aaagccaccc tggtgtgcct
ggccaccggc tttttccccg accacgtgga gctgtcttgg 1440tgggtgaacg
gcaaagaggt gcacagcggg gtctccaccg acccccagcc cctgaaagag
1500cagcccgccc tgaacgacag ccggtactgc ctctcttctc ggctgagagt
gtccgccacc 1560ttctggcaga acccccggaa ccacttccgg tgccaggtgc
agttctacgg cctgagcgag 1620aacgacgagt ggacccagga cagagccaag
cctgtgaccc agatcgtgtc tgccgaggcc 1680tgggggcgcg ccgattgcgg
cttcaccagc gtgtcctacc agcagggcgt gctgtctgcc 1740accatcctgt
acgagatcct gctgggcaag gccaccctgt acgccgtgct ggtgtccgcc
1800ctggtgctga tggctatggt gaagcggaag gacttctgat aa
1842301815DNAArtificial SequenceSynthetic Polynucleotide
30atggcactga gcagcctgct gaaggtggtc accgccagcc tgtggctggg ccctggaatc
60gcccagaaga tcacccagac ccagcccggc atgttcgtgc aggaaaaaga ggccgtcacc
120ctggactgca cctacgacac cagcgacccc agctacggcc tgttctggta
caagcagccc 180agcagcggcg agatgatctt cctgatctac cagggcagct
acgaccagca gaacgccacc 240gagggccggt acagcctgaa cttccagaag
gcccggaagt ccgccaacct ggtcatcagc 300gccagccagc tgggcgacag
cgccatgtac ttttgcgcca tgaccagcgg cttcggcaac 360gagaagctga
ccttcggcac cggcacccgg ctgaccatca tccccaacga catccagaac
420cccgagcccg ccgtgtacca gctgaaggac cccagaagcc aggacagcac
cctgtgcctg 480ttcaccgact tcgacagcca gatcaacgtg cccaagacaa
tggaaagcgg caccttcatc 540accgacaaga ccgtgctgga catgaaggct
atggacagca agagcaacgg cgccattgcc 600tggtccaacc agaccagctt
cacatgccag gacatcttca aagagacaaa cgccacctac 660ccctccagcg
acgtgccctg tgacgccacc ctgaccgaga agtccttcga gacagacatg
720aacctcaact tccagaacct gagcgtgatg ggcctgcgga tcctgctgct
gaaagtggcc 780ggcttcaacc tgctgatgac cctgcggctg tggtccagcc
gggccaagag atctggcagc 840ggcgccacca acttcagtct gctgaagcag
gccggcgacg tggaagagaa ccctggccct 900atgggcccag gcctgctgca
ttggatggcc ctgtgtctgc tgggcaccgg acacggcgac 960gctatggtca
tccagaatcc cagataccag gtcacacagt tcggcaagcc cgtgaccctg
1020agctgcagcc agaccctgaa ccacaacgtg atgtactggt atcagcagaa
gtccagccag 1080gcccccaagc tgctgttcca ctactacgac aaggacttca
acaacgaggc cgacaccccc 1140gacaacttcc agagcagacg gcccaatacc
agcttctgct tcctggacat caggagccct 1200gggctgggcg acgctgctat
gtacctgtgt gccaccagca gaggccaggg aggacagcct 1260cagcactttg
gcgacggcac cagactgagc atcctggaag atctgcggaa cgtgaccccc
1320cccaaggtgt ccctgttcga gcccagcaag gccgagatcg ccaacaagca
gaaagccacc 1380ctcgtgtgcc tggccagagg cttcttcccc gaccacgtgg
aactgtcttg gtgggtcaac 1440ggcaaagagg tgcacagcgg cgtcagcacc
gaccctcagg cctacaaaga gagcaactac 1500agctactgcc tgagcagtcg
gctgcgggtg tccgccacct tctggcacaa cccccggaac 1560cacttcagat
gccaggtgca gttccacggc ctgagcgaag aggacaagtg gcccgagggc
1620agccccaagc ctgtcaccca gaacatcagc gccgaggcct ggggcagagc
ctgtggcatc 1680accagcagct accagcaggg cgtgctgagc gccaccatcc
tgtacgagat cctgctgggc 1740aaggccaccc tgtacgccgt gctggtgtcc
accctggtgg tcatggctat ggtcaagcgg 1800aagaacagct gataa
181531672DNAHomo Sapiens 31atgaacggag acgacgcctt tgcaaggaga
cccacggttg gtgctcaaat accagagaag 60atccaaaagg ccttcgatga tattgccaaa
tacttctcta aggaagagtg ggaaaagatg 120aaagcctcgg agaaaatctt
ctatgtgtat atgaagagaa agtatgaggc tatgactaaa 180ctaggtttca
aggccaccct cccacctttc atgtgtaata aacgggccga agacttccag
240gggaatgatt tggataatga ccctaaccgt gggaatcagg ttgaacgtcc
tcagatgact 300ttcggcaggc tccagggaat ctccccgaag atcatgccca
agaagccagc agaggaagga 360aatgattcgg aggaagtgcc agaagcatct
ggcccacaaa atgatgggaa agagctgtgc 420cccccgggaa aaccaactac
ctctgagaag attcacgaga gatctggaaa tagggaggcc 480caagaaaagg
aagagagacg cggaacagct catcggtgga gcagtcagaa cacacacaac
540attggtcgat tcagtttgtc aacttctatg ggtgcagttc atggtacccc
caaaacaatt 600acacacaaca gggacccaaa aggggggaac atgcctggac
ccacagactg cgtgagagaa 660aacagctggt ga 672329PRTHomo sapiens 32Lys
Tyr Ser Glu Lys Ile Ser Tyr Val1 5339PRTHomo sapiens 33Lys Phe Ser
Glu Lys Ile Ser Cys Val1 5349PRTHomo sapiens 34Lys Ser Leu Glu Lys
Ile Ser Tyr Val1 53591PRTHomo sapiens 35Ala Gln Lys Ile Thr Gln Thr
Gln Pro Gly Met Phe Val Gln Glu Lys1 5 10 15Glu Ala Val Thr Leu Asp
Cys Thr Tyr Asp Thr Ser Asp Pro Ser Tyr 20 25 30Gly Leu Phe Trp Tyr
Lys Gln Pro Ser Ser Gly Glu Met Ile Phe Leu 35 40 45Ile Tyr Gln Gly
Ser Tyr Asp Gln Gln Asn Ala Thr Glu Gly Arg Tyr 50 55 60Ser Leu Asn
Phe Gln Lys Ala Arg Lys Ser Ala Asn Leu Val Ile Ser65 70 75 80Ala
Ser Gln Leu Gly Asp Ser Ala Met Tyr Phe 85 903690PRTHomo sapiens
36Asp Ala Met Val Ile Gln Asn Pro Arg Tyr Gln Val Thr Gln Phe Gly1
5 10 15Lys Pro Val Thr Leu Ser Cys Ser Gln Thr Leu Asn His Asn Val
Met 20 25 30Tyr Trp Tyr Gln Gln Lys Ser Ser Gln Ala Pro Lys Leu Leu
Phe His 35 40 45Tyr Tyr Asp Lys Asp Phe Asn Asn Glu Ala Asp Thr Pro
Asp Asn Phe 50 55 60Gln Ser Arg Arg Pro Asn Thr Ser Phe Cys Phe Leu
Asp Ile Arg Ser65 70 75 80Pro Gly Leu Gly Asp Ala Ala Met Tyr Leu
85 903727PRTArtificial SequenceSynthetic 37Arg Ala Lys Arg Ser Gly
Ser Gly Ala Thr Asn Phe Ser Leu Leu Lys1 5 10 15Gln Ala Gly Asp Val
Glu Glu Asn Pro Gly Pro 20 253881DNAArtificial SequenceSynthetic
38cgggccaagc ggtccggatc cggagccacc aacttcagcc tgctgaagca ggcgggcgac
60gtggaggaga accccggccc c 81
* * * * *